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ABSTRACT 
Monique Ahinee Amamoo: Impact of Automatic Reporting of Estimated Glomerular 
Filtration on Chronic Kidney Disease Detection and Patient Care in a Hospital Setting 
(Under the direction of Gerardo Heiss) 
BACKGROUND AND OBJECTIVES  
In an attempt to address rising concerns about low and delayed detection of chronic 
kidney disease (CKD) several healthcare organizations and clinical laboratories developed 
initiatives to automatically report estimated glomerular filtration rates (eGFR) in response to 
the National Kidney Foundation-Kidney Disease Outcome Quality Initiative (KDOQI) 
clinical recommendations. In April 2005 the University of North Carolina at Chapel Hill 
Healthcare System (UNCHS), introduced an eGFR reporting initiative to facilitate 
monitoring of CKD in its patient population. This initiative automatically reports eGFR 
levels calculated using the Modification of Diet in Renal Disease (MDRD) equation on all 
serum creatinine tests ordered for adults 18 and older. This doctoral dissertation examined 
the impact of the UNCHS eGFR reporting initiative on CKD detection and nephrology 
appointments.  
DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS 
This study used administrative billing and electronic medical record data from adult 
patients who sought care in the University of North Carolina at Chapel Hill Healthcare 
System from 2004-2010 and had at least one serum creatinine measurement. Patient 
demographics, CKD diagnosis, comorbidities, and laboratory results were retrieved from 
medical records. Billing data was used to determine nephrology scheduling status.  Measures 
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of CKD detection and nephrology appointments were compared for the 15 months prior, and 
the 48 months following the introduction of the initiative to automatically report eGFR. 
RESULTS 
An increase of 9% in the overall detection of CKD within the UNC healthcare system 
was observed following the introduction of the eGFR reporting initiative. Those with 
moderate CKD, older age, male gender, white race and CKD risk factors had higher 
detection rates during the period following the introduction of the eGFR reporting initiative, 
but no detectable differences in scheduled nephrology appointments were observed following 
the UNCHS eGFR reporting initiative. Those with diagnoses of hypertension, diabetes and 
cardiovascular disease had lower odds of having a nephrology appointment scheduled, 
irrespective of eGFR reporting period.  
CONCLUSIONS 
 Introduction of automated eGFR reporting was followed by a moderate increase in CKD 
detection. eGFR reporting had no discernible association with scheduling of nephrology 
appointments within UNCHS. 
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CHAPTER ONE: BACKGROUND AND SIGNIFICANCE 
 
The Epidemiology of Chronic Kidney Disease 
Chronic Kidney Disease (CKD) is an escalating public health issue affecting one in 
ten Americans with another 20 million at risk. In 2007, approximately 26.3 million Americans 
were living with CKD (Stages 1-4), representing 13.1 % of the US non-institutionalized adult 
population.[1]  
The Burden of CKD is progressively increasing.  The prevalence of CKD has 
increased from 10.1% in 1988-1994 to 14.0% in 2005-2010.[1, 2] The number of individuals 
with Stage 5 CKD also referred to as end-stage kidney disease (ESKD), has increased 
dramatically from 14,500 in 1978 to 527,283 in 2007 and 593,086 in 2010.[2-4]   
CKD has been associated with demographic factors. Age is associated with an 
increased prevalence of CKD.[5-9] Among participants in the National Health and Nutrition 
Examination Survey (NHANES) (2005-2010), the prevalence of CKD increased with age and 
was highest among those 60 years and older (35.0%)[2]. CKD prevalence is also higher among 
women compared with men (15.8% vs. 12.1%) and African Americans compared with Whites 
(16.0% vs. 14.3%) [2, 6, 8-13] In NHANES 1999-2000,  the prevalence of CKD was 26% higher 
among women compared to men and varied by race-ethnicity for Whites (4.2%), African-
Americans (3.4%), and Mexican-Americans (1.2%) [8].
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 Low socio-economic status (SES) and life-course SES are also associated with 
CKD.[14-19] Less than a high school education was associated with an increased odds of CKD 
for  both African-Americans and Whites compared with those with a college degree in the 
Atherosclerosis Risk in Communities Study (OR=1.6, 95% CI (1.1, 2.5) for African-Americans; 
OR=1.75, 95% CI (1.2, 2.5) for Whites)[18]. An investigation of life -course socioeconomic 
status revealed, the odds of CKD among middle-aged participants who reported working when 
30 years old were higher than those participants who reported  being unemployed when they 
were 30 years old (OR=1.4; 95% CI (1.0, 2.0) for Whites; OR=1.9, 95% CI (1.2, 3.0) for 
African-Americans)[18].  
 
Burden of Chronic Kidney Disease 
CKD causes premature morbidity and mortality. CKD is associated with 2-3 fold increase 
in the risk of all-cause mortality.[8] Patients with CKD are at increased risk for complications 
from infections, strokes, and premature cardiovascular diseases.[3, 8] Additionally, those with 
CKD are hospitalized at higher rates than those without CKD, even after adjusting for prior 
hospitalizations, comorbidities and sex.[3]   
Kidney disease has a substantial impact on the health care system. CKD patients, 
compared to -age-matched patients without CKD, experience more health care costs, physician 
visits, prescriptions, and are twice as likely to be hospitalized.[20]  The costs of delivering care 
to ESKD patients in 1999 was estimated at 17.9 billion dollars, 13% higher than the total 
National Institutes of Health (NIH) budget for the year[21]. The total Medicare expenditures for 
ESKD care in 2010 rose by 8.01% to $32 billion, which represented 6 % of the total Medicare 
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budget[2]. Healthcare costs associated with CKD and ESKD are increasing.  In 2006 the 
healthcare costs for CKD patients with Medicare were $49 billion, nearly 5 times the costs of 
care in 1993.  Similarly, the healthcare cost for those with an Employer Health Group Plan in 
2006  was 11 times greater, at $1.2 billion, than the costs in 2000 [22].  
Detection and Treatment of Chronic Kidney Disease 
CKD is asymptomatic, and when left untreated can progress to complete kidney 
failure or end-stage kidney disease (ESKD).  ESKD is a chronic disease for which the only 
treatments are dialysis and transplantation. The incidence of ESKD has doubled every year since 
1980, and an estimated 385,200 people in the U.S. currently live with ESKD.  By 2030, the 
estimated number of new cases of ESKD will exceed 450,000, and over 2 million people will be 
on dialysis  [23]. CKD and ESKD lower patient quality of life, cause premature morbidity and 
mortality, and cause economic burden on individuals, health care systems and society.[20] 
However, if chronic kidney disease is detected early, treatments can be successful in slowing the 
progression to kidney failure.[24-27]  
Clinical Practices to Detect Chronic Kidney Disease 
For years clinical practices used serum creatinine (SCr) levels as a surrogate marker for 
kidney filtration because of the ease and cost effectiveness of this measurement. Due to the 
limitations of SCr to adequately measure kidney function, estimating glomerular filtration rate 
(eGFR) equations were developed. National Kidney Foundation (NKF) clinical 
recommendations[28] support the use of the abbreviated Modification of Diet in Renal Disease 
Study (MDRD) equation to help facilitate an easier mechanism for estimating GFR.[29]  
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GFR=186* [SCr]
-1.154
 *[Age]
-0.203 
*[0.742 if female]*[1.212 if black]. 
Physicians manually estimate kidney function using the MDRD equation and use the 
current established National Kidney Foundation- Kidney Disease Outcomes Quality Initiative 
(NKF-KDOQI) workgroup clinical guidelines[28] for defining the stages of CKD.   
 
Table 1- Stages of Chronic Kidney Disease 
Stage Description GFR 
(mL/min/1.73m
2
) 
1 Kidney damage* with normal or     GFR ≥90 
2 Kidney damage* with normal or     GFR 60-89 
3 Moderate    GFR 30-59 
4 Severe    GFR 15-29 
5 Kidney failure  <15 (or dialysis) 
*Kidney damage is defined as any structural or functional abnormalities of the kidney 
detected by pathological abnormalities or by the presence of sediments, blood, or 
proteinuria in the urine[30]. 
 
Automatic eGFR reporting facilitates earlier detection. In 1999, The National Kidney 
Foundation- Kidney Disease Outcome Quality Initiative (KDOQI) developed guidelines to 
identify and manage kidney disease at earlier stages.[28]  The KDOQI guidelines recommended 
that all laboratories automatically report eGFR, calculated using the MDRD equation, whenever 
serum creatinine (SCr) is measured. The implementation of this automatic reporting eliminates 
the need for physicians to manually determine eGFR and helps facilitate the early detection of 
CKD.   
Currently, eight US states (Connecticut, New Jersey, New York, Louisiana, Michigan, 
Pennsylvania, Tennessee, and Texas)[31] and several healthcare agencies have passed state 
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policies requiring automatic eGFR reporting. Many international and US-based healthcare 
organizations and laboratories implemented policies that would automatically report eGFR when 
SCr is measured [31-35].  Although the utility and role of automatic eGFR reporting remains 
unsettled, studies have shown that eGFR reporting resulted in increased CKD detection, 
referrals, consults, and first time visits to nephrology clinics [34, 36-40].  
Based upon recommendations from the North Carolina Institute of Medicine Task Force 
on Chronic Kidney Disease[41], the University of North Carolina at Chapel Hill Healthcare 
system (UNCHS), voluntarily implemented automatic eGFR reporting in April 2005.  UNCHS 
implemented a system-wide CKD initiative to automatically report eGFR (based on the MDRD 
equation), on all SCr tests ordered on adults 18 years or older. Along with this voluntary 
mandate, the UNCHS collaborated with the UNC Kidney Center to develop education programs 
for health professionals and the general population, to increase CKD awareness among 
healthcare providers and improve detection. 
Early Detection and Intervention Can Reduce Burden of Disease 
Patients referred earlier to nephrologists have fewer CKD complications and lower 
mortality rates, than those who are referred late.[42] The 5-year survival rate for ESKD is 2 
times as high for those who are referred to nephrologists early, at least 6 months prior to dialysis, 
compared to those referred late, (less than 6 months prior to dialysis), 72.4% vs. 35.2%, 
respectively[43]. Nephrology referrals in the early disease stages reduce the likelihood that 
patients will require emergency dialysis, and increase the likelihood of receiving standard renal 
therapy or pre-dialysis transplantations [44, 45]. Once CKD is detected, kidney protective 
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treatments can be successful in slowing the progression to kidney failure and facilitating the 
optimal management of co-morbid conditions.[24-27] 
 
Despite knowledge that early detection is the key to slowing the progression of kidney 
disease, many patients are getting delayed referrals to nephrologists. Studies have documented 
primary care physician referrals to nephrologists range from 15 to 83%.[46] Late referrals to 
nephrologists have resulted in higher hospitalization rates, late initiation of dialysis, higher 
mortality rates, increased incidence of anemia, bone disease and other CKD complications [47-
50]. Approximately 20-35% of those starting dialysis are due to late referrals.  However, if 
patients are referred earlier to nephrologists CKD complications and mortality rates can be 
reduced.[42] 
 
Screening for CKD is necessary for identifying early CKD patients and ensuring 
timely referral to nephrologists. In 1999, The National Kidney Foundation- Kidney Disease 
Outcome Quality Initiative (KDOQI) developed guidelines to identify and manage kidney 
disease.  The KDOQI guidelines recommend that all physicians assess clinical and socio 
demographic factors associated with kidney disease such as family history of kidney disease, 
older age, smoking, low birth weight, hypertension or diabetes during each patient’s health care 
visit. If any of these factors are identified in the patients, then kidney function, through an 
assessment of albuminuria and GFR should be estimated to screen for chronic kidney disease. 
Within the KDOQI guidelines, recommendations were made to increase the CKD screening 
practices within health care systems. However, health care systems have failed to provide regular  
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CKD screenings for patients.[46] Lack of awareness and policy mandates could be barriers to 
detecting and preventing kidney disease.  
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CHAPTER TWO: SPECIFIC AIMS AND RATIONALE 
 
Chronic kidney disease (CKD) is a growing public health concern affecting more than 26 
million Americans [10].  CKD is often asymptomatic and, if untreated, may progress to end-
stage kidney disease (ESKD) requiring dialysis therapy and organ transplantation. Early 
diagnosis and management of kidney disease can delay or prevent the development of ESKD 
and minimize CKD mortality, through the management and treatment of complications 
associated with CKD such as, cardiovascular disease, hypertension, anemia, decreased 
quality of life and metabolic bone disease. [42, 48, 50] 
CKD is under-recognized and under-diagnosed. In the National Health and Nutrition 
Examination Survey (NHANES) (1999 -
 
2000), 2% of US adults age 20 and older reported 
having a history of weak or failing kidneys [8]. Furthermore, less than 20% of people with 
moderate CKD (Glomerular filtration rate (GFR) of 30 to 59 ml/min per 1.73 m
2
) and the 
presence of albuminuria reported knowing they had weak or failing kidneys (18.2%) [8]. 
This lack of CKD recognition is of concern for patients and clinicians. A previous study 
reported primary care physicians did not include ICD-9 diagnostic codes for CKD for 89% of 
patients with moderate CKD (GFR of 30 to 59 ml/min per 1.73 m
2
) [51].  To improve CKD 
diagnosis and awareness, the National Kidney Foundation (NKF) implemented several 
education programs and clinical recommendations, including the automatic reporting of 
estimated Glomerular Filtration Rate (eGFR).[52] 
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The implementation of automatic eGFR reporting elicited debate among health 
professionals about its utility and role in the early detection and management of CKD. One 
view maintains that automatic eGFR reporting will provide kidney function assessments 
directly to physicians who previously had to calculate eGFR by hand using estimating 
equations.  This simplification of the reporting of eGFR may lead to an increased awareness 
of CKD among physicians and other health professionals and earlier identification of patients 
for the initiation of treatment of CKD.  An opposing view argues that automatic eGFR 
reporting will be used as a population-level screening program for CKD, which could result 
in increased diagnoses of CKD, for patients who may never progress to ESKD. However, 
there is no scientific evidence to adequately identify CKD patients that will progress to 
ESKD, and the therapeutic interventions available to slow the progression from CKD to 
ESKD must be implemented during the early disease stages.  
Although the utility and role of automatic eGFR reporting remains unsettled, studies in 
international populations have shown that eGFR reporting have resulted in increased CKD 
detection, referrals, consults, and first time visits to nephrology clinics.[36-40]  However, the 
impact of automatic eGFR reporting policies on CKD awareness, detection, and treatment 
warrant further investigation in US populations. In April 2005, the University of North 
Carolina Healthcare System (UNCHS) voluntarily implemented a system-wide CKD 
initiative that includes the automatic reporting of eGFR, calculated using the Modification of 
Diet in Renal Disease (MDRD) equation on all serum creatinine tests ordered. The goal of 
this initiative was to facilitate the early diagnosis of CKD and improve early medical 
management to minimize CKD burden among UNCHS patients.  In the years since this 
initiative began, the impact of this administrative decision has yet to be evaluated.  
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We sought to evaluate the impact of automatic eGFR reporting within UNCHS on the 
identification of CKD patients and nephrology referrals within the UNC Nephrology clinics 
between the years 2004-2010.  The aims to address the study focus are detailed below. 
Specific Aim 1: Impact of eGFR reporting on CKD detection among at-risk population 
To quantify the detection of  CKD detection prior to and following the implementation of 
automatic eGFR reporting among adults patients who had at least one SCr measurement with 
an eGFR measurement below 60ml/min/1.73m
2 
seen in the UNC Healthcare System (UNCHS) 
between January 2004 and December 2010.  
Hypothesis: CKD detection will increase by at least 10% from before to after the 
implementation of automatic eGFR reporting in April 2005. 
Rationale: To determine if eGFR reporting helps increase the detection of CKD among adults 
at-risk for CKD detection in the UNC Healthcare System (UNCHS). 
 
Specific Aim 2: Impact of eGFR reporting on adherence to National Kidney Foundation 
CKD guidelines 
 
To quantify the proportion of adults who had a second SCr measurement after an initial 
eGFR <60 ml/min/1.73m
2
 before and after the implementation of automatic eGFR reporting 
seen in the UNC Healthcare System (UNCHS) between January 2004 and December 2009,  
Hypothesis for Aim 2: Adherence to CKD guidelines will increase by at least 10% from 
before to after the implementation of automatic eGFR reporting in April 2005. 
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Rationale: To quantify the proportion of adherence to CKD guidelines among the sub-
population of at-risk CKD patients.  
 Specific Aim 3: Impact of eGFR reporting on the clinical diagnosis of CKD given two 
eGFR measurements <60ml/min./1.73m
2
. 
To quantify the detection of clinically identified CKD before and after the implementation of 
automatic eGFR reporting among adult patients with lab-verified moderate to severe CKD 
(i.e. two eGFR measurements below 60ml/min/1.73m
2
) seen in the UNC Healthcare System 
(UNCHS) between January 2004 and August 2009.  
Hypothesis for Aim 3: Diagnostic labeling of CKD in patients with two eGFR 
measurements below (60ml/min./1.73m
2
) will increase by at least 10% from before to 
after the implementation of automatic eGFR reporting in April 2005. 
Rationale: To quantify CKD detection among adults with lab-verified CKD in the UNC 
Healthcare System (UNCHS). 
Specific Aim 4: Impact of eGFR reporting on referrals to nephrology 
To examine the proportion of nephrology referrals to UNC Nephrology clinics for adult 
patients with stage 3 CKD or higher before and after the implementation of automatic 
eGFR reporting in the UNCHS  
 
Hypothesis for Aim 4: Referrals to a nephrologist will increase by 25% after the 
implementation of automatic eGFR reporting compared to before automatic eGFR 
reporting. 
 
 12 
 
Our study sought to expand the current body of chronic kidney disease detection 
research and to gain a greater understanding, of how automatic eGFR reporting impacts 
detection and patient care. It also sought to identify which sub-populations eGFR 
reporting benefitted most in terms of detection and referral to help provide a foundation 
upon which public health, medical professionals and policy makers can inform future 
clinical recommendations for screening, detection and patient care for CKD.  
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CHAPTER THREE: RESEARCH PLAN AND METHODS 
 
Study Design Overview 
To examine how automatic eGFR reporting in hospitals and clinical practices impact 
CKD detection and care management, we conducted a data analysis of administrative claims 
data and electronic medical records from the University of North Carolina Hospital System 
(UNCHS).  
 
Study Setting 
Participants for this cross-sectional study were selected from the University of North 
Carolina Hospital System (UNCHS). UNCHS is a state owned integrated not-for profit 
healthcare system based in Chapel Hill, NC. This academic medical center provides services 
for children, women, psychiatric and neurologic patients, and general adult patient care. 
UNCHS provides service to patients regardless of their ability to pay.  There are currently 
about 2,000 faculty physicians and physicians-in-training providing care for UNCHS 
patients.  Of the 400,000 UNCHS patients seen in 2009, 55% were women, 42% were 
minority, and 10% were uninsured. UNCHS provides care for patients from all 100 counties 
of North Carolina, with the top counties being Orange, Wake, Alamance, Durham, Chatham 
and Cumberland counties, and also served patients from multiple Southeastern US states.
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Study Population 
This study included adult patients, age 18- 70, who were seen in the UNCHS between 
January 1, 2005 and December 31, 2010 and had at least one serum creatinine measurements and 
no previous history of kidney disease. Patient race, sex, and a serum creatinine measurement are 
required to assess eGFR. Therefore, patients with an unknown race or sex, or a missing a serum 
creatinine lab were also excluded from the study. 15,945 patients with at least one low eGFR 
measurement less than 60/ml/min/1.73m
2
 were identified. Nine hundred and one were excluded 
due to having a history of kidney disease, leaving 15,044 patients in the base study population.  
For Aim 2, two thousand three hundred and seventy-five patients were excluded because there 
was no identifiable 2
nd
 SCr lab.  Six thousand fifty-eight were excluded because they did have 
not moderate to severe CKD (GFR>60 mL/min/1.73m2). (Figure 1) 
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Figure 1: Study Exclusion Criteria 
 
Data Source 
Administrative claims data was obtained from the WebClinical Information Systems 
(WebCIS), the laboratory information system, an accounting system and the UNC Physicians 
and Associates (UNC P&A) Billings data. WebCIS is a repository of electronic medical records 
developed in 1992 to help facilitate access to all UNCHS medical records and to allow patients 
to be followed in both in-patient and out-patient settings.[53] Clinical and administrative 
information such as patient demographics, laboratory and pathology results, medical imaging 
and prescribed medications are currently available in WebCIS. Clinical information from 
WebCIS was linked to the laboratory information system coordinated by McClendon Clinical 
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Laboratories. This system coordinates and integrates all UNHS Clinical Laboratory and 
Anatomic Pathology services including serum creatinine labs.  The patient’s International 
Classification of Diseases (version 9) (ICD-9) diagnoses came from Trendstar, a McKesson 
Information System accounting system, used in the UNCHS to coordinate billing and insurance 
claims for all patients. Information about scheduled nephrology appointments were obtained 
from the UNCHS Appointment scheduling system and diagnosis information for the study were 
obtained from UNC P&A data files.  UNC P&A is the billing department for UNC faculty 
practice within the Healthcare system.  
 
Data Acquisition and Creation 
Project data was abstracted by the North Carolina Translational Science Institute 
(NCTRaCS), Clinical Data Warehouse for Health (CDW-H). CDW-H is a biomedical 
informatics resource that manages and mines all UNC Hospital clinical and research data, 
ranging from billing and insurance to diagnosis and medication information. It was established in 
2008 to enhance the quality of care and clinical research with the UNCHS patient population. 
CDW-H contains data from clinical and operations systems within UNCHS, primarily from 
WEBCIS. After CDW-H project requests was submitted to the governance committee and 
approved the requested research data was made available to the study investigators.   
  NCTRACS queried the UNCHS records to identify all SCr labs between January 1, 2004 
and December 31, 2010. 1,643,782 labs were identified. The study investigator identified and 
flagged all individuals (N= 82,645) that had at least two SCr labs 3 months apart. Identified 
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patient ids were sent back to NCTRaCS to obtain patient characteristics, lab results, provider 
information, and health status/ co morbidities. Nephrology appointment data was obtained from 
UNC P&A appointment scheduling system, to identify whether or not patients were scheduled an 
appointment after a low eGFR value. The data files sent to obtain study data are listed below. 
Additional description of the excel files that were sent are described in detail in Appendix 1. 
 DX (Contained all diagnosis identified for patients in UNCHS) 
 Postal Code (Contained information on the billing addresses for patients.) 
 Demog (Contained the race, date of birth, gender of patients in UNCHS) 
 Lab (Contained that laboratory results for the GFR labs) 
 Outpatientvisits (identified the clinic the patient was seen in during the UNCHS 
visit) 
 Payor (Identified the billing payor for the UNCHS visit) 
 Problems (identified patient’s comorbidities listed in the medical record) 
 Visits (identified the inpatient admission information for the corresponding 
UNCHS visit) 
 NephAppts (identified the scheduled nephrology appointments for the 
corresponding UNCHS visit) 
 NephVisits (Contained hospital billing data for Nephrology clinic visits earlier 
than 12/31/2010) 
 NephVisitInsurers  (Contained patients' insurance data for Nephrology clinic 
visits earlier than 12/31/2010) 
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After the acquisition of the data files from NCTRACS, each excel data file was converted to a 
SAS data file. The files were combined using the unique identifiers that connect each data set. 
The identifiers used for each data set are disclosed in Appendix Table 1.    
Study Variables 
Laboratory Verified Chronic Kidney Disease (Aim 1) 
 
Prior to the automatic reporting of eGFR in 2005, GFR was calculated manually using 
the  abbreviated Modification of Diet in Renal Disease (MDRD) equation.[29]  This study 
calculated GFR for those patients seen prior to the implementation of the automatic reporting, 
before April 2005. For those patients with clinic visits after April 2005, eGFR was abstracted 
from WebCIS as automatically reported patient their lab results. Individuals with two eGFR 
measures below 60mL/min/ 1.73m
2
 were classified as having laboratory verified CKD.  
Individuals for whom one or both of the eGFR values were above 60mL/min/ 1.73m
2 
were 
classified as having normal kidney function. 
Assessment of CKD detection (Aim1) 
 
For patients identified as having laboratory verified CKD, the medical record 
corresponding  to the second SCr lab result was examined for any indication of CKD diagnosis 
via ICD-9 codes in the discharge report. If any of the CKD codes in Table 2 were indicated in the 
discharge records then the patient was labeled has having detected CKD.  If no indication of a 
CKD diagnosis was present in the discharge record, then the patient was identified as having 
undetected CKD.  
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Table 2- Diagnosis Codes used for the Definition of Chronic Kidney Disease Documentation 
Diagnosis ICD-
9CM 
codes 
Chro ic kidney disease 585 or 585.1- 585.5 
Proteinuria 791.0 
Unspecified disorder of kidney and ureter 593.9 
Hematuria 599.7 
Malignant hypertensive renal disease with renal failure 403.01 
Benign hypertensive renal disease with renal failure 403.11 
Unspecified hypertensive renal disease with renal failure 403.91 
Malignant hypertensive heart and renal disease with renal 
failure 
404.02 
Malignant hypertensive heart and renal disease with heart 
failure and renal failure 
404.03 
Benign hypertensive h art and renal disease with renal 
failure 
404.12 
Benign hypertensive heart and renal disease with heart 
failure and renal failure 
404.13 
Unspecified hypertensive heart and renal disease with renal 
failure 
404.92 
Unspecified hypertensive heart and renal disease with heart 
failure and renal failure 
404.93  
 
Assessment of scheduled nephrology appointment (Aim4)  
Patients must be referred by a physician in order to be seen by a nephrologist.  However, 
due to the limited capabilities of the medical records, referrals to nephrologist outside of the 
UNCHS are not consistently captured. For the purposes of this study the information regarding 
referrals will only apply to those nephrologists in the UNCHS and defined as having a scheduled 
nephrology appointment. The appointment scheduling system was queried to determine if 
patients had any nephrology appointments scheduled after the flagged low eGFR. If an 
appointment was identified then the patient was labeled as having a scheduled appointment; if no 
identified appointments were identified, they were labeled as no labeled appointment. 
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Changes in CKD Function (Aim 4) 
For those with a scheduled nephrology appointment laboratory records were searched to 
identify follow-up SCr measurements during the 12 months following the initial nephrology 
visit. Laboratory records were also searched for SCr measurements over 12 months following the 
initial laboratory value for patients who did not have a scheduled nephrology visit.  Change in 
CKD function was based upon these subsequent lab values and categorized as No Change, 
Increase in Stage (deterioration of kidney function) and Decrease in Stage (improvement of 
kidney function). No change was defined as those who had no change in their subsequent GFR 
level compared to the initial lab; an increase in staging was defined by the decrease in GFR 
levels in the subsequent lab when compared to the initial lab. For example a reduction in GFR 
from 15-29mL/min/1.73m
2
 to <15mL/min/1.73m
2
 would be categorized as an increase in stage. 
Lastly, a decrease in stage is when the subsequent GFR level is higher than the initial GFR lab 
value. For example an individual whose initial lab value is 15-29mL.min/1.73m
2 but
 has a
 
subsequent lab value one year later that increases to 30-59 mL/min/1.73m
2
, they would be 
categorized as decrease in stage. 
Exposure: Timing of Healthcare Visit 
  
 The exposure of interest was the timing of the healthcare visit, determined by whether or 
not the patient was seen in the UNCHS before or after the implementation of the automatic 
eGFR reporting. If the service date of the patient’s UNC Hospital visit was between the dates 
January 1,2004 and April 30, 2005, inclusive, then the patient was seen prior to the 
implementation of the automatic eGFR reporting and are considered unexposed. However, 
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patients were considered exposed if they were seen at UNCHS between the dates May 1, 2005 
and December 31, 2010, after the implementation of the automatic eGFR reporting.  
 
Additional variables 
This study also examined patient demographics, health status/co-morbidities, and 
provider information.  These covariates were abstracted from the medical records and 
accounting system data. See Appendix 2 for description of each study covariate, data source, 
variable type, and categorization, if applicable. Patient’s family history of kidney disease and 
socioeconomic status were not captured in the medical record and were not being examined in 
this study.  
 
Data Analysis 
Tabular analyses were used to examine the frequency of patient characteristics overall 
and separately within the eGFR reporting period. Crude associations between eGFR reporting 
period and study outcomes were examined using contingency tables. Associations between 
eGFR reporting periods and CKD detection were assessed using linear risk regression models 
and log-risk regression models. Multiple logistic regression was used to examine the effect of 
automatic eGFR reporting on scheduled nephrology appointments. Ordinal tests of association 
within strata were conducted to examine associations between reporting period and changes in 
CKD stage stratified by initial CKD stage.  Effect measure modification and confounding were 
assessed and accounted for in final analyses.   
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To identify characteristics associated with CKD detection, scheduled nephrology 
appointments and changes in GFR, bivariate relationships between each outcome and each 
covariate were examined overall and by eGFR reporting period. A nominal level of statistical 
significance of 0.05 was used to identify associations with covariates. All analyses were 
conducted using SAS software (version 9.2, SAS Institute, Cary, NC).   
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CHAPTER FOUR: PAPER 1- AUTOMATIC EGFR REPORTING AND DETECTION 
OF CHRONIC KIDNEY DISEASE 
Background 
 Persistent kidney dysfunction, known as CKD, is an ever growing issue plaguing society.  
CKD prevalence has increased 30%, from 10.1% in 1988-1994 to 13.1% in 1999-2004 [1]. 
While accurate estimates of CKD stages 1-4 are not available, the incidence of Stage 5 CKD, or 
end-stage kidney disease (ESKD), increased from 86.2 per million population in 1980 to 350.8 
per million population in 2008.  The care of  ESKD patients  consumes roughly 6% of the US 
Medicare budget [54].   CKD and ESKD lower a patient’s quality of life and causes economic 
burden on individuals, health care systems and society[20]. However, with early detection and 
treatment of CKD can be successful in slowing the onset and progression to ESKD [3, 8, 24-27].    
Despite the high burden of CKD, awareness and detection of kidney disease in the US is 
low among consumers and providers of health. [8, 55-59]. According to the 2004 NHANES 
survey less than 10 percent of  US adults  with moderate (eGFR of 30 to 59 mL/min/1.73m
2
) and 
24% of those with severe (eGFR of 15 to 29 mL/min/1.73m
2
) kidney dysfunction report ever 
being detected, or told that they have weak or failing kidneys[8].  Similarly, in a large US 
managed care cohort (> 10,000 people), only 14%  of patients with eGFR <60 mL/min/1.73 m
2 
were documented as having CKD [60].  A cross-sectional study of adults over 40 years old 
reported that primary care physicians did not include International Classification of Diseases 
Version 9 (ICD-9) diagnostic codes for CKD for 89% of these patients with moderate CKD. 
[51]. 
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Many international and US-based healthcare organizations and laboratories implemented 
policies that automatically report eGFR when SCr is measured [34, 61, 62], eliminating the time 
and effort of manual calculations.  Studies of international populations have shown that 
automatic eGFR reporting resulted in increased CKD detection, referrals, consults, and first time 
visits to nephrology clinics [36-40]. In contrast, the impact of eGFR reporting in US healthcare 
systems remains unclear [34, 61, 62]. 
On April 27, 2005 the University of North Carolina Healthcare System (UNCHS) 
implemented a system-wide CKD initiative to report eGFR automatically, using the MDRD 
equation, on all patients ≥ 18 years of age who underwent SCr measurements. Two memoranda 
were distributed and dissemination sessions were held to inform all health care providers in the 
system of this initiative. The goal of the automatic eGFR reporting initiative was to increase 
reporting efficiency, facilitate the early diagnosis of CKD, and improve early medical 
management to minimize CKD burden among UNCHS patients. We evaluated whether eGFR 
reporting improved detection and CKD awareness in a public tertiary US hospital system and 
determined which demographic factors and comorbid conditions were associated with CKD 
detection. 
 
Methods 
All inpatients and outpatients 18 to 70 years of age who received services at the UNCHS 
between January 2004 to August 2009, and had at least one eGFR value less than 60 
mL/min/1.73m
2 
were selected for inclusion in this study (n=15,945). Patients were excluded if 
they: (1) had, prior history of kidney disease (N=901); (2) no identifiable 2
nd
 SCr measurement 
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(N=2375); and (3) eGFR > 60 mL/min/1.73m
2
 (N= 6058) after the 2nd SCr measurement (Figure 
2).  
Medical record and laboratory data were extracted from the electronic health record at the 
UNCHS’s Web Clinical Information System. Diagnoses and procedures coded by ICD-9 were 
obtained from Trendstar, an accounting system used for billing and insurance claims. The 
institutional review board of The University of North Carolina School of Medicine, as well as the 
UNC Hospital Governance Board for access to the UNCHS data approved this study. 
 
Medical records were used to determine race/ethnicity and age at initial clinic visit. 
Comorbidities were labeled based upon the presence of at least one ICD-9 code in the medical 
record within one year prior to the date of the initial low eGFR measurement. The comorbidities 
and corresponding ICD-9 codes included: diabetes mellitus (250.x); essential hypertension 
(401.x, 402.x); and cardiovascular disease (CVD) (410.x-414.x, 428.x, 429.2, 430-438). 
Patient’s health insurance was determined as the last known insurance identified in the medical 
records and categorized as private (Blue Cross/ Blue Shield, CHAMPUS, commercial insurance 
carriers and HMO/PPO), public (Medicaid, Medicare A or Medicare B), or no insurance. 
Patients with worker’s compensation or whose medical care was paid for by UNC were 
classified as having no health insurance coverage. Ease of access to healthcare was calculated as 
the number of miles between the patient’s billing address and the UNC clinic location.  
 
The eGFR reporting period was determined by the timing of the patient’s UNCHS visit 
relative to the implementation of the automatic eGFR reporting initiative in the UNCHS. The 
eGFR reporting period was considered pre-initiative if the service date of the patient’s UNCHS 
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visit was between January 1, 2004 and April 27, 2005 inclusive, and post-initiative if the 
UNCHS visit was after April 27, 2005. The eGFR was manually calculated for patients seen 
prior to the implementation of automatic reporting (January 2004 and April 2005) using the 
MDRD equation[29]:   
 
eGFR=  186*[SCr]-1154*[age] -0.203 *[0.742 if female]*[1.212 if African American] . 
 
For patients whose clinic visits/admissions occurred after April 2005, eGFR was 
abstracted from the electronic health record. Individuals with two eGFR measures below 
60mL/min/ 1.73m
2
 were classified as having laboratory verified CKD.  Individuals for whom 
one or both of the eGFR values are above 60mL/min/ 1.73m
2
 were classified as not having 
CKD and thus excluded from this study. 
 
The UNCHS medical records were searched for detected CKD, defined as having at least 
one discharge ICD-9 code of 585.x within one year of the lab date.  If no indication of CKD 
diagnosis was identified in subsequent medical records after one year then the patient was 
labeled as undetected CKD.  The date of the first visit with an ICD-9 code indicating CKD was 
considered the detection date. The one-year CKD detection rates were determined before and 
after eGFR reporting for the study cohort. 
 
Statistical Analysis  
Tabular analyses were used to examine the frequency of patient characteristics overall 
and separately within the eGFR reporting period. Crude associations between eGFR reporting 
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period and CKD detection were examined using contingency tables. Linear risk regression 
models were used to estimate the 1 year cumulative incidence (CI) and difference (CID) of 
CKD detection in the study cohort pre- and post-initiative. Log-risk regression models were 
used to estimate the incident risk ratios (RR) and 95% Confidence Intervals (CI) pre- vs. post 
initiative. Effect measure modification and confounding were assessed and accounted for in 
final analyses.   
 
To identify characteristics associated with CKD detection, bivariate relationships 
between CKD detection and each covariate were examined overall and by eGFR reporting 
period. Significantly associated covariates (p<0.05) were simultaneously entered into an 
adjusted multivariate linear risk model; univariate and adjusted cumulative incidence of 
detection ratios (CIR) and 95% confidence intervals were presented. All analyses were 
conducted using SAS software (version 9.2, SAS Institute, Cary, NC).   
 
Results 
We identified 6,611 patients with 2 low eGFR values (< 60 ml/min/1.73m
2
). Overall, the 
majority of this study’s population were identified as having eGFR levels of 30-59 
mL/min/1.73m
2 
(74%), female (57%), white (59%), and over the age of 40 (90%). Forty-nine 
percent of the patients had a history of hypertension, 25% had a history of diabetes and 20% had 
a history of CVD.  Private health insurance was reported in 36% of patients, and most study 
patients travelled less than 50 miles to UNCHS for care (66%) while 35% travelling less than 20 
miles (Table 3). 
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The characteristics of the cohort of individuals seen prior to the reporting initiative are 
similar to those seen in UNCHS post-initiative, with some exceptions. There was a higher 
proportion of individuals with comorbidities post-initiative, compared to pre-initiative 
(hypertension (55% vs. 35%), diabetes (28% vs. 19%) and CVD (24% vs. 13%)). While most 
patients had public and or private health insurance, more pre-initiative patients were missing 
health insurance information compared to post-initiative patients (19% vs. 0.01%, respectively) 
(Table 3).   
Of the 6,611 patients in the study, 16.6 % (n=1096) were labeled as having detected CKD 
within one year of lab-verified CKD date. More were detected after the implementation of eGFR 
reporting (15.6% pre-initiative vs. 17.1% post-initiative). No effect measure modification or 
confounding was identified for detection of CKD by hypertension, diabetes, gender, race, age, 
CVD, insurance, or distance to UNCHS.  
Stratified analyses were conducted to examine sub-groups that may benefit from eGFR 
reporting. Detection rates after the eGFR reporting initiative were found to be significantly 
higher than the rates before reporting initiative for those with moderate CKD (Stage III eGFR of 
30-59 mL/min/1.73m
2
), older age, males, Whites, and those with comorbidities. Individuals with 
moderate CKD had a detection rate that was 131% higher post eGFR reporting than pre-initiative 
(CID=2.31; 95% CI: 1.89, 2.82). Detection rates were 48% higher post eGFR reporting initiative 
than before reporting for those age 60-70 years (CID=1.48; 95% CI: 1.195, 1.86).  Males and 
Whites were detected at a 19% and 35% higher rate, respectively, post-initiative than pre-
initiative (males CID=1.19; 95% CI: 1.01, 1.40; whites CID=1.35; 95%CI: 1.18, 1.63). 
Individuals with a history of diabetes (CID=1.37; 95% CI: 1.08, 1.76), hypertension (CID=1.31; 
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95% CI: 1.08, 1.59) and CVD also had a higher detection rate post-initiative than pre-initiative 
(Table 4). 
When examining the diffusion of innovation effect on CKD detection among the sub-
populations that benefited from eGFR reporting, we determined that the greatest increase in 
CKD detection within these groups occurred during the 2
nd
 and 3
rd
 years after implementation 
(Figure 3 and Table 5). However, this increase in detection was not sustained thereafter; with a 
decline in the CKD detection rates for most groups back to the initial CKD detection rate pre-
initiative. 
Factors found to be independently associated with CKD detection pre-initiative were 
eGFR (<0.001), older age (<0.001), race (0.025) and sex (0.0067) (Table 6). In reference to 
eGFR levels, those with eGFR levels of 15-29 mL/min/1.73m
2
 and eGFR <15 mL/min/1.73m
2
 
were significantly more likely to be detected than those who had an eGFR 30-59 mL/min/1.73m
2 
(CIR=4.27; 95% CI: 3.32, 5.48; and CIR=7.31; 95% CI: 5.87, 9.09 respectively). African 
Americans were 2.23 times as likely to be detected as Whites (CIR=2.23; 95%CI: 1.82, 2.74), 
and females were less likely to be detected than males pre-initiative (CIR: 0.76; 95%CI: 0.62, 
0.93).   
Similar factors were found to be independently associated with CKD detection post-
initiative: eGFR level (0.0035), race (0.0013), and sex (<0.001). In addition, hypertension 
(0.0027), diabetes (<0.001) and CVD (<0.001) were also associated with CKD detection post-
initiative. Those with an eGFR 15-29 mL/min/1.73m
2 
(stage IV) were 1.96 times more likely to 
be detected than those with moderate (stage III) eGFR level (CIR=1.96; 95% CI: 1.67, 2.29). 
African Americans were 58% more likely to be detected than whites (CIR=1.58; 95% CI: 1.38, 
1.80). Additionally those factors found to be associated post-initiative were history of CVD 
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(CIR=1.48; 95% CI: 1.30, 1.70), diabetes (CIR=1.52; 95%CI: 1.33, 1.73), and hypertension 
(CIR=1.22; 95% CI: 1.07, 1.40) as shown in Table 6. 
 
Discussion 
We examined the effect of automatic eGFR reporting on CKD detection rates in a 
Southeastern USA tertiary referral center and found that automatic eGFR reporting moderately 
increased the overall detection of CKD by approximately 9%. More significantly, among those 
with moderate CKD (Stage III, eGFR: 30-59 mL/min/1.73m
2
), there was an increase of 131% 
CKD detection after the implementation of eGFR reporting. We found that older age, male 
gender, white race and a history of hypertension, diabetes or CVD were associated with an 
increase in CKD detection after implementation of eGFR reporting when compared to pre-
initiative reporting. We also identified the eGFR reporting initiative had the greatest impact of 
CKD detection during the second year of implementation, but the increase in CKD detection was 
not sustained. Lastly, we found that eGFR level, age, race, and sex were independently 
associated CKD detection both pre-initiative and post-initiative. We also found that having 
comorbidities was independently associated with post automatic eGFR reporting. 
 
The increase in detection among those with moderate CKD indicates that eGFR reporting 
potentially benefits those who may have otherwise gone undetected until reaching more 
advanced stages of CKD. The association between African American race and CKD detection 
was also noted in a previous study of in-patients only at UNCHS during a similar study period 
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[63]. This may indicate that health providers are aware that CKD disproportionally affects this 
minority group, but in contrast with other reports [26], we did not detect a sex difference.  
  
Most studies that have examined the impact of automatic eGFR reporting have shown 
that implementation resulted in increased CKD detection rates. A US based Veteran Affairs 
study showed a 7% improvement in CKD detection; however overall CKD detection was low 
with only 10% of those with stage III (eGFR 30-59 min/mL/m
2 
) identified [64]. A study of 
hospitalized elderly patients showed that there was a significant increase in CKD detection after 
implementation of eGFR reporting, although there was no change in physician prescribing 
patterns [61]. Similarly, a United Kingdom-based study reported an increase in detection after 
the implementation of eGFR reporting [65].   
 
As in previous reports [9, 60, 62], we found that overall CKD detection rates were low, 
emphasizing the need to develop ongoing efforts to educate health professionals. Studies by 
Akbari et al. and Richards et al, showed that provider education and care management techniques 
coupled with the implementation of eGFR reporting improves the identification rate of CKD [66, 
67].  Although some efforts were taken to inform providers of the implementation of automatic 
eGFR reporting in the UNCHS, no well-defined provider education program was established, 
which may have contributed to the unexpected decrease in CKD detection after eGFR reporting 
started. 
 
Our study limitations include a potential misclassification of CKD. Current CKD 
guidelines define CKD as persistent kidney dysfunction with or without the presence of kidney 
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damage. Automatic eGFR reporting only assesses kidney dysfunction through serum creatinine 
measures and not the presence of protein in a patient’s urine. Patients with kidney damage who 
would meet clinical criteria for CKD were not identified in our study. ICD-9 codes are often 
used to identify CKD and related conditions (e.g. proteinuria and nephrotic syndrome).  Use of 
the latter codes may capture additional patients with CKD, but would also increase 
misclassification of CKD.  Thus, we chose to define CKD using ICD-9 code 585 to ensure the 
ascertainment of CKD labeling and not that of other related kidney diseases.  
 
A further limitation of this report is that, information was only available for the 15 
months prior to the implementation of the automated eGFR reporting. The short timeframe for 
pre-eGFR reporting may have constrained our ability to estimate the true detection of CKD prior 
to automated eGFR reporting. The time available for identification of comorbidities and patient 
characteristics was limited to one year prior to the clinic visit date associated with the second low 
eGFR measurement, pre- and post- initiative, to minimize differential misclassification with 
respect to eGFR reporting period.  
 
UNCHS is a referral center, and it is possible patients may have had a second low eGFR 
measurement assessed at a center external to UNCHS, and thereby received a diagnosis of CKD 
prior to UNCHS’s documentation of a second low eGFR. A sensitivity analysis was conducted to 
examine the risk of CKD detection among patients after their first low eGFR value. Results from 
the sensitivity analyses indicated similar detection patterns as those in the overall study, with a 
lower CKD detection post-initiative reporting, than pre- initiative reporting. The detection rates 
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among this group did not differ with respect to magnitude or direction. Thus, selection bias due 
to the definition of lab-verified CKD should not significantly alter these results.  
 
Beyond the aforementioned limitations, this study has several strengths. The database 
includes a combination of hospital and patient level data for a large sample of individuals within 
a US based tertiary care hospital system. The UNCHS provides care for a racially and 
economically diverse population of patients.  The distribution of the overall sample population 
with 33% being African American and a fairly equal distribution of those with public vs. private 
insurance is consistent with both the general population of NC and the general demographics of 
the patients cared for the UNCHS.  
 
We observed that the implementation of automatic eGFR reporting slightly increased the 
identification of individuals with CKD within a tertiary healthcare system. As the post-initiative 
rate of detection remained low, these data suggest an opportunity to increase education and 
awareness about eGFR among healthcare professionals. Examining whether changes in referral 
patterns to nephrologists occurred following the introduction of automated eGFR reporting 
remains an important clinical practice question.  
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Identify the first lab with GFR 
value less than 60 
ml/min/1.74m2 
(N=15,945) 
Has no prior history of kidney 
disease (N=15,044)  
 
Has prior history of kidney 
disease (N=901) 
 
 
No identifiable 2nd SCR lab 
(N=2375) 
 
Identify individuals who 
obtained a second lab 90 or 
more days away (N=12,669) 
 
CKD Stage 1-2 (N=6058) 
 
Has Lab-verified CKD  
Stage 3-5 
(N=6,611)  
 
Figure 2 Study Population Exclusion/ Inclusion Flow Chart 
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Table 3-Characteristics Of Lab-Verified CKD Patients (2004-2010) At the UNCHS 
(Overall and by eGFR Reporting Period)  
 
 
Characteristics 
Overall 
(N=6611) 
Pre-Initiative 
Jan2004-April 2005 
(N=2119) 
Post-Initiative 
May 2005-Dec 
2009 
(N=4492) 
 N      % N      % N      % 
eGFR level
†
  30-59 mL/min/1.73m
2
 4,880 (73.8) 1,554(73.3)        3,326(74.0) 
15-29 mL/min/1.73m
2
 755 (11.4) 307(14.5) 448(10.0) 
 <15 mL/min/1.73m
2
 976 (14.8) 258(12.2) 718(16.0) 
 Males 2,866 (43.4) 928(43.8) 1,938(43.1) 
Females 3,745 (56.6) 1,191(56.2) 2,554(56.9) 
 Whites
‡
 3,884 (58.8) 1,207(57.0) 2,677(59.6) 
African-Americans 2,159 (32.7) 775(36.6) 1,384(30.8) 
Other race 568 (8.6) 137(6.5) 431(9.6) 
18-39 years of age 675 (10.2) 260(12.3) 415(9.2) 
40-59 years of age 3,049 (46.1) 953(45.0) 2,096(46.7) 
60-70 years of age 2,887 (43.7) 906(42.8) 1,981(44.1) 
Hypertension
§
 3,212 (48.6) 748(35.3) 2,464(54.9) 
Diabetes
§
 1,672 (25.3) 397(18.7) 1,275(28.4) 
Cardiovascular disease
§
 1,349 (20.4) 268(12.6) 1,081(24.1) 
No Health Insurance** 552 (8.3) 130(6.1) 422(9.4) 
Public Insurance 2,182 (33.0) 687(32.4) 1,495(33.3) 
Private Insurance 2,373 (35.9) 659(31.1) 1,714(38.2) 
Public & Private Insurance 1,026 (15.5) 240(11.3) 786(17.5) 
Missing Health Insurance information 478 (7.2) 403(19.0) 75(1.7) 
Miles traveled to UNC: Less than 20 miles
*** 
2,307 (34.9) 691(32.6) 1,616(36.0) 
20-49 miles  2,048 (31.0) 617(29.1) 1,431(31.9) 
50-99 miles  1,291 (19.5) 410(19.3) 881(19.6) 
More than 100 miles  589 (8.9) 171(8.1) 418(9.3) 
Missing Distance  376 (5.7) 230(10.9) 146(3.3) 
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Characteristics 
Overall 
(N=6611) 
Pre-Initiative 
Jan2004-April 2005 
(N=2119) 
Post-Initiative 
May 2005-Dec 
2009 
(N=4492) 
No Health Insurance** 552 (8.3) 130(6.1) 422(9.4) 
Public Insurance 2,182 (33.0) 687(32.4) 1,495(33.3) 
Private Insurance 2,373 (35.9) 659(31.1) 1,714(38.2) 
Public & Private Insurance 1,026 (15.5) 240(11.3) 786(17.5) 
Missing Health Insurance information 478 (7.2) 403(19.0) 75(1.7) 
Miles traveled to UNC: Less than 20 miles
*** 
2,307 (34.9) 691(32.6) 1,616(36.0) 
20-49 miles  2,048 (31.0) 617(29.1) 1,431(31.9) 
50-99 miles  1,291 (19.5) 410(19.3) 881(19.6) 
More than 100 miles  589 (8.9) 171(8.1) 418(9.3) 
Missing Distance  376 (5.7) 230(10.9) 146(3.3) 
*All data were derived from UNC Healthcare System data for 2004-2010. The study population included patients with lab verified CKD Stage 3 
or higher during 2004-2010. Patients with unknown race, gender and age, and previous kidney disease were excluded. The eGFR reporting period 
was determined by the timing of the patient visit relative to the implementation of the automatic eGFR reporting initiative in the UNCHS before 
April 2005 (Pre-); after April 2005 (Post-). 
† eGFR level was determined based on the abbreviated Modification of Diet in Renal Disease (MDRD) equation.  
‡ Based on the race/ethnicity reported in medical record.  'Other' race includes all patients with race/ethnicity identified as American Indian, 
Asian/Pacific Islander, Hawaiian, or Other race. 
§ Patients with comorbidities identified in medical records (via ICD-9 codes) at least once within one year prior to clinic visit were identified 
classified as having Hypertension (401,402); Diabetes (250, 250.5, and 250.5); CVD (410-414,428, 429.2, 430-438) 
**Health insurance coverage was determined based upon the insurance that was identified in the medical records within 60 days of the visit. 
Private (Blue Cross, CHAMPUS, Commercial, HMO/PPO) Public (Medicaid, Medicare A, Medicare B), No Health Coverage (Self-Pay, 
Workers’ Compensation). . Data are missing for patients with unknown insurance. 
***Miles traveled to UNCHS based upon the distance between UNCHS and patient address  
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Table 4- Association Between eGFR Reporting Period and CKD Detection 
 
Table 
Overall 
 N (%) 
Pre-Initiative 
Jan2004-April 
2005 
N (%) 
Post-Initiative 
May 2005-Dec 
2009 
N (%) 
Cumulative 
Incidence of 
Detection Ratio
a
 
(95%CI) P-value 
 N      % N      % N      % 
  
Overall 1,096 (16.6) 330(15.6) 766(17.1) 1.09(0.97,1.23) 0.1327 
eGFR level
b
   
30-59 mL/min/1.73m
2
 
643 (13.2) 108(6.9) 535(16.1) 2.31(1.89,2.82) <.0001 
15-29 mL/min/1.73m
2
 232 (30.7) 91(29.6) 141(31.5) 1.06(0.85,1.32) 0.5931 
 <15 mL/min/1.73m
2
 221 (22.6) 131(50.8) 90(12.5) 0.25(0.20,0.31) <.0001 
18-39 years of age 158 (21.4) 79(29.0) 79(17.0) 0.58(0.44,0.77) 0.0001 
    40-59 years of age 569 (18.0) 162(16.5) 407(18.6) 1.13(0.95,1.33) 0.1612 
    60-70 years of age 369 (13.6) 89(10.3) 280(15.2) 1.48(1.19,1.86) 0.0006 
Females 514 (13.7) 163(13.7) 351(13.7) 1.00(0.85,1.19) 0.9622 
Males 582 (20.3) 167(18.0) 415(21.4) 1.19(1.01,1.40) 0.0350 
Whites
d
 515 (13.3) 129(10.7) 386(14.4) 1.35(1.12,1.63) 0.0017 
African-Americans 500 (23.2) 185(23.9) 315(22.8) 0.95(0.81,1.12) 0.5565 
Other race 81 (14.3) 16(11.7) 65(15.1) 1.29(0.77,2.15) 0.3278 
Hypertension
c
 564 (17.6) 106(14.2) 458(18.6) 1.31(1.08,1.60) 0.0063 
Diabetes
c
 353 (21.1) 65(16.4) 288(22.6) 1.37(1.08,1.76) 0.0099 
Cardiovascular disease
c
 290 (21.5) 45(16.8) 245(22.7) 1.35(1.01,1.8) 0.0415 
Miles traveled to UNC: 
Less than 20 miles 
367 (15.9) 107(15.5) 260(16.1) 1.04(0.84,1.28) 
0.7166 
Traveled 20 to 49 miles  375 (18.3) 101(16.4) 274(19.1) 1.17(0.95,1.44) 0.1391 
Traveled  50 to 99 miles 209 (16.2) 59(14.4) 150(17.0) 1.18(0.90,1.56) 0.2348 
Traveled more than 100 
miles 
72 (12.2) 18(10.5) 54(12.9) 1.22(0.74,2.03) 
0.4248 
a Cumulative Incidence Risk Ratios were estimated using Log-risk regression models (Post vs. Pre initiative risks) 
bCKD Stage was determined based on the abbreviated Modification of Diet in Renal Disease (MDRD) equation. 
c Patients with comorbidities identified in medical records (via ICD-9 codes) at least once within one year prior to clinic visit 
were identified classified as having Hypertension (401,402); Diabetes (250, 250.5, and 250.5); CVD (410-414,428, 429.2, 430-
438) 
d Based on the race/ethnicity reported in medical record.  'Other' race includes all patients with race/ethnicity identified as 
American Indian, Asian/Pacific Islander, Hawaiian, or Other race. 
e Miles traveled to UNCHS based upon the distance between UNCHS and patient address 
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Table 5-Period Analysis: Stratified estimates of CKD Detection (Overall and according to eGFR 
reporting) Summary of Cumulative Incidence of Detection Ratio (95%CI) by Period 
 
STRATIFIED 
GROUP 
ALL ELIGIBLE 
PATIENTS 
(N=6611) 
1 year after 
reporting 
initiative 
(N=3240) 
2 years after 
reporting 
initiative 
(N=3112) 
3 years after 
reporting 
initiative 
(N=3306) 
4 years after 
reporting 
initiative 
(N=3048) 
Overall 1.09(0.97,1.23) 1.17(1,1.37) 1.17(0.99,1.38) 1.03(0.88,1.22) 1.07(0.89,1.27) 
CKD
a
  Stage III: 
30-59 
2.31(1.89,2.8) 2.4(1.89,3.05) 2.52(1.98,3.21) 2.26(1.79,2.8) 2.32(1.8,2.99) 
Age 60-70 1.48(1.19,1.86) 1.42(1.05,1.9) 1.73(1.3,2.31) 1.5(1.13,2) 1.28(0.92,1.78) 
Male 1.19(1.01,1.40) 1.23(0.99,1.53) 1.21(0.96,1.53) 1.17(0.94,1.45) 1.2(0.95,1.51) 
Whites 1.35(1.12,1.63) 1.37(1.07,1.76) 1.44(1.12,1.85) 1.32(1,1.68) 1.32(1.01,1.72) 
Hypertension
b
 1.31(1.08,1.59) 1.43(1.1,1.81) 1.41(1.11,1.8) 1.2(0.94,1.54) 1.26(0.96,1.64) 
Diabetes
b
 1.37(1.08,1.76) 1.46(1.08,1.96) 1.62(1.21,2.17) 1.13(0.82,1.56) 1.3(0.93,1.8) 
Cardiovascular 
disease
b
 
1.35(1.01,1.8) 1.39(0.99,1.95) 1.5(1.07,2.12) 1.23(0.87,1.75) 1.28(0.88,1.87) 
aCKD Stage was determined based on the abbreviated Modification of Diet in Renal Disease (MDRD) equation. 
b Patients with comorbidities identified in medical records (via ICD-9 codes) at least once within one year prior to clinic visit 
were identified classified as having Hypertension (401,402); Diabetes (250, 250.5, and 250.5); CVD (410-414,428, 429.2, 430-
438) 
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Figure 3- Period Analysis: Stratified estimates of Relative Risk of CKD Detection 
 
 
CKD= Chronic Kidney Disease 
eGFR= estimated GFR  
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Table 6- Factors Associated With CKD Detection Before And After eGFR Reporting Period 
(Crude) 
 
 
 Pre-Initiative 
Jan2004-April 2005 
Post-Initiative 
May 2005-Dec 2009 
 
Cumulative 
Incidence of 
Detection Ratio
a
 
(95%CI) 
p-
value 
Cumulative Incidence 
of Detection Ratio
a
 
(95%CI) p-value 
eGFR level
b
   
30-59 mL/min/1.73m
2
 
Ref. 
<0.001 
Ref. 
0.0035 
15-29 mL/min/1.73m
2
 4.27 (3.32, 5.48)  1.96 (1.67, 2.29)  
 <15 mL/min/1.73m
2
 7.31 (5.87, 9.09)  0.78 (0.63, 0.96)  
Age 
    18 to 39 years 
Ref. 
<0.001 
Ref. 
0.9479 
     40 to 59 years  0.57 (0.45, 0.72)  1.10 (0.88, 1.37)  
     60 to 70 years  0.35 (0.27, 0.46)  0.90 (0.71, 1.13)  
Race 
     White 
Ref. 
0.0025 
Ref. 
0.0013 
African American 2.23 (1.82, 2.74)  1.58 (1.38, 1.80)  
Other race 1.09 (0.67, 1.78)  1.05 (0.82, 1.33)  
Gender 
     Male 
Ref. 
 
Ref. 
<0.001 
Female 0.76 (0.62, 0.93) 0.0067 0.64 (0.56, 0.73) <.0001 
No Cardiovascular disease Ref.  Ref.  
Cardiovascular disease 1.09 (0.82, 1.45) 0.5541 1.48 (1.30, 1.70) <.0001 
No Diabetes Ref.  Ref.  
Diabetes 1.06 (0.83, 1.36) 0.6249 1.52 (1.33, 1.73) <.0001 
No Hypertension Ref.  Ref.  
Hypertension 0.87 (0.70, 1.07) 0.1908 1.22 (1.07, 1.40) 0.0027 
Miles traveled to UNCHS: 
      Less than 20 miles Ref. 0.2867 Ref. 0.9809 
20 to 49 miles  1.06 (0.82, 1.36)  1.19 (1.02, 1.39)  
50 to 99 miles 0.93 (0.69, 1.25)  1.06 (0.88, 1.27)  
More than 100 miles 0.68 (0.42, 1.09)  0.80 (0.61, 1.05)  
Health Insurance     
   Private Insurance Ref. 0.0513 Ref. 0.4088 
Public  Insurance 1.47 (1.14, 1.89)  1.20 (1.03, 1.39)  
Public and Private 
Insurance 
1.32 (0.94, 1.87) 
 
0.77 (0.62, 0.95) 
 
No Insurance 1.10 (0.68, 1.77)  1.29 (1.04, 1.59)  
a Cumulative Incidence(CI) of Detection Risk Ratios: CI of Detection (group1) vs  CI of Detection (Reference)  
bCKD Stage was determined based on the abbreviated Modification of Diet in Renal Disease (MDRD) equation. 
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CHAPTER FIVE: IMPACT OF AUTOMATIC ESTIMATED GLOMERULAR 
FILTRATION REPORTING ON SCHEDULED NEPHROLOGY APPOINTMENTS 
AND KIDNEY FUNCTION IN A TERTIARY MEDICAL INSTITUTION 
 
 
INTRODUCTION 
Chronic kidney disease (CKD) affects more than one in ten Americans with an additional 
20 million at risk. Approximately 13.1 % of the US non-institutionalized adult population is 
living with CKD.[1]. In the Medicare population, the prevalence of CKD has increased by over 
200% from 1999 to 2009, 2.4% vs. 7.9%, respectively.  
Once CKD is detected, treatments to delay the progression of kidney disease can be 
employed thereby reducing the patient morbidity and financial burden associated with end stage 
kidney disease (ESKD) management [24-27]. Nephrology referrals in the early disease stages 
also reduce the likelihood that patients will require emergency dialysis, and increase the 
likelihood of receiving standard renal therapy or a pre-dialysis transplant [44, 45]. Patients with 
CKD who are referred to nephrologists early have fewer complications and lower mortality rates 
than those who are referred late, [42] reducing the burden to the healthcare system. The 5-year 
survival rate for ESKD among those referred to nephrologists at least 6 months prior to dialysis 
is twice that of those who are referred later, less than 6 months prior to dialysis, (72.4% vs. 
35.2%, respectively) [43]. 
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To aid in identifying and managing kidney disease earlier, the National Kidney Foundation- 
Kidney Disease Outcome Quality Initiative (KDOQI) developed guidelines [52] that 
recommended estimated glomerular filtration rates (eGFR), based on the Modification of Diet in 
Renal Disease (MDRD) equation  be reported concurrently with any serum creatinine (SCr) 
measurement. This recommendation eliminated the need for physicians to manually determine 
eGFR and thus help facilitate the early detection of CKD[52].   
Many international and US-based healthcare organizations and laboratories implemented 
policies to automatically report eGFR when SCr is measured [31, 32, 37, 68, 69].  Although the 
utility [31, 32, 35, 38, 43, 52, 68, 70, 71] and role of automatic eGFR reporting remains 
unsettled, studies have shown that automatic eGFR reporting resulted in increased CKD 
detection, referrals, consults, and first time visits to nephrology clinics [34, 36-40, 68].  
The aims of our study were to evaluate whether the implementation of automatic eGFR 
reporting increased scheduled nephrology appointments among patients with a low eGFR 
measurement compared to the period prior to automatic eGFR reporting and to examine patient 
characteristics related to scheduling of nephrology appointments. Few studies have had an 
opportunity to examine the impact automatic eGFR reporting has on eGFR levels as a result of 
scheduled nephrology appointments, while others report the paucity of data examining this 
patient outcome [38, 67, 72]. Our study also sought to evaluate changes in CKD function by 
automatic eGFR reporting periods among those with and without a scheduled nephrology 
appointment. 
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Methods 
Automatic eGFR reporting: 
The University of North Carolina Healthcare System (UNCHS) implemented a system-
wide CKD initiative to automatically report eGFR (based on the MDRD equation), on all SCr 
tests ordered on adults 18 years or older in April 2005.  Two memos were distributed and 
dissemination sessions were held to inform all physicians, and health care providers in the 
system of the new initiative.   
 
Study Population 
Patients in the UNCHS, ages 18-70 years old, with no previous history of kidney disease 
and who had at least one eGFR value less than 60 mL/min/1.73m2 from January 2004-December 
2010 were included in this study (N=15,044).   Patients with prior UNCHS nephrology clinic 
visits were excluded (N=204). 
 Data Source:  
The patients’ sex, race, comorbidities, and GFR levels were identified from the clinical 
medical records and laboratory information in the UNCHS WebClinical Information System 
(WebCIS). Information about scheduled nephrology appointments were obtained from the 
UNCHS appointment scheduling system. Patient’s age at visit, diagnoses, and primary insurance 
coverage were obtained from the administrative billings claims data from Physicians and 
Associates, the billings organization that processes all claims for the UNCHS. All data were 
retrieved by the North Carolina Translational Science Institute Clinical Data Warehouse for 
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Health, a biomedical informatics resource that manages all UNCHS clinical and research data. 
The Institutional Review Board of The UNC School of Medicine, as well as the UNCHS 
Governance Board approved this study. 
Measurements  
The categorization of race/ethnicity included African American, White, and Other race 
(American Indian, Asian/Pacific Islander, Hawaiian, Hispanic, or Other race).  The patient’s age 
was determined as the number of years between birth date and clinic visit date.  Morbidity was 
defined by at least one diagnosis code (International Classification of Diseases, Ninth Revision, 
Clinical Modification (ICD-9-CM)) in the medical record within one year prior to the date of the 
low eGFR measurement, and included diabetes mellitus (ICD-9-CM: 250, 250.5), essential 
hypertension (ICD-9-CM: 401 and 402), and cardiovascular disease (ICD-9-CM: 410-
414,428,429.2,430-438). Initial kidney function levels were categorized using the stages of CKD 
(3:30-59 mL/min/1.73m
2
; 4:15-29 mL/min/1.73m
2
; 5:< 15 mL/min/1.73m
2
).  
Patient’s health insurance was categorized as no insurance, private (Blue Cross/ Blue 
Shield, CHAMPUS, commercial insurance carriers and HMO/PPO), public (Medicaid, Medicare 
A or Medicare B), and a combination of both public and private insurance. Those lacking 
insurance information in the data source were categorized as missing insurance information.   
The eGFR reporting period was defined as pre-initiative and post-initiative.  Patients 
were categorized as pre-initiative if their first visit date was prior to April 2005.  Conversely, 
patients with service dates after April 2005 were categorized as post-initiative.   
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Assessment of eGFR 
Estimates of eGFR were identified in two ways.  For patients whose service date 
occurred after April 2005 (post-initiative), the eGFR value was abstracted from WebCIS.  For 
patients whose service date occurred before April 2005 (pre-initiative), the MDRD equation was 
used to calculate patients’ eGFR, consistent with the method used by UNCHS’ automated eGFR 
reporting via WebCIS.  
 
Nephrology Scheduled Appointments and Visits 
The UNCHS appointments scheduling database was searched to determine if an 
appointment was scheduled for the patient within one year following a low eGFR measurement. 
If no indication of an appointment was identified in the appointment scheduling system, the 
patient was classified as having no scheduled nephrology appointment.  
Patient Outcomes via Change in CKD Function 
Laboratory records were searched to identify follow-up SCr measurements within 12 
months following the initial nephrology visit to determine eGFR and CKD stage, for those with a 
scheduled nephrology appointment. Similarly, laboratory records were also searched for SCr 
measurements within 12 months following the initial laboratory value, for patients who did not 
have a scheduled nephrology visit.  Change in CKD function was determined as the difference 
between CKD stage at the last SCr measurement and the CKD stage at the initial SCr 
measurement. The change was categorized as 1) no change, 2) deterioration of kidney function 
and 3) improvement of kidney function. Those whose subsequent eGFR lab level is the same as 
the initial lab eGFR level are defined as No change; a deterioration of kidney function was 
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defined by the decrease in eGFR levels in the subsequent lab when compared to the initial lab. 
For example a reduction in eGFR from 15-29mL/min/1.73m
2
 to <15mL/min/1.73m
2
 would be 
categorized as a deterioration in function. Lastly, when the subsequent eGFR level was higher 
than the initial eGFR lab value the change is defined as an improvement of kidney function 
occurred. For example an individual whose initial lab value was 15-29mL.min/1.73m
2 
and a
 
subsequent lab value one year later was 30-59 mL/min/1.73m
2
, would be categorized as an 
improvement in kidney function. 
  
Statistical Analysis:  
Summary statistics stratified by eGFR reporting period were obtained using basic 
descriptive analyses.  The effect of automatic eGFR reporting on scheduled nephrology 
appointments was examined using multiple logistic regression. Characteristics associated with a 
scheduled nephrology appointment, after a low eGFR value, were identified by examining 
bivariate relationships between CKD detection and each covariate, overall and within subgroups. 
A nominal level of statistical significance of 0.05 was used to identify associations with 
covariates. Bivariate relationships between the outcome and each covariate, stratified by eGFR 
reporting period were used to determine patient characteristics associated with scheduled 
nephrologist appointments before and after reporting implementation. Within strata ordinal tests 
of association were conducted to examine associations between reporting period and changes in 
kidney function stratified by initial CKD stage.  All analyses were conducted using SAS 
software (version 9.2, SAS Institute, Cary, NC).   
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Results 
Baseline Characteristics 
We identified 14,840 patients with an eGFR less than 60 mL/min/1.73m
2
 Overall, 86.5% 
of the study population had an eGFR between 30-59 mL/min/1.73m
2
, and approximately 7% had 
more severe kidney disease with an eGFR of < 15 mL/min/1.73m
2
. The majority of patients were 
women (57%), 30% were African American and 50% were aged 40-59 years. Approximately 
87% percent had public, private or some combination of health insurance.  Thirty-three percent 
of the patients had a history of hypertension, 14.6% a history of diabetes, 14.5% a history of 
CVD (Table 7).  A total of 5,467 patients were identified pre-initiative, 9,373 were post-
initiative.   
 
Characteristics Associated With Scheduled Nephrology Visit 
Only 15% of the study population (N=2,156) had a scheduled a nephrology appointment 
within one year in the UNCHS whereas 85% (N=12,684) did not have a scheduled appointment 
within one year in the UNCHS. A higher proportion of those with lower eGFR values had a 
scheduled a nephrology appointment compared to those with higher eGFR values (Stage 5 57%, 
Stage 4 32%, Stage 3 9.8%). (Table 7)   Similarly, a higher proportion of African Americans had 
scheduled appointments compared to whites (20.1% vs. 11.9%). Younger patients and those who 
travel the furthest distance to UNCHS had higher proportions of scheduled appointments. 
Whereas the cohort of patients with both public and private health insurance had higher 
proportions of scheduled appointments compared to those with either insurance type or no 
insurance at all. (Table 7)  
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Characteristics Associated With Automatic eGFR Reporting and Scheduled Nephrology 
Visits  
 
The proportion of patients with a low eGFR measurement who were scheduled for a 
nephrology appointment were similar for the pre-initiative period and post-initiative period of 
automatic eGFR reporting (14.9% pre-reporting vs. 14.3% post-reporting). Among those with 
scheduled appointments, 816 patients were identified during the period before automatic eGFR 
reporting and 1340 during the period after automatic eGFR reporting. (Table 8) 
The proportion of scheduled visits was higher post eGFR reporting initiative then pre 
eGFR reporting among  individuals with an eGFR level of <15mL/min/1.73m
2
 (28.6% vs. 23.8 
%), those aged 40-59 (50.0% vs. 55.9%) and those individuals with previous history of known 
risk factors for CKD (hypertension (14.8% vs. 29.4%); diabetes (8.9% vs. 15.4%); and CVD 
(6.1% vs. 10.1%). Conversely, individuals with eGFR between 15-29 mL/min/1.73m
2
 and aged 
25-39 (17.3% vs. 21.2%) had a lower proportion of scheduled appointments post eGFR reporting 
initiative compared to pre-eGFR reporting initiative. However, no differences in the proportion 
of scheduled visits pre reporting and post reporting were observed for sex, race, health insurance 
and health access (Table 8). 
Individuals with eGFR levels between 15-29 mL/min/1.73m
2
 and eGFR <15 
mL/min/1.73m
2
 were significantly more likely to schedule a nephrology visit pre-initiative than 
those with eGFR between 30-59 mL/min/1.73m
2 
(OR=3.94; 95% CI: 3.17, 4.90; and OR=5.99; 
95% CI: 4.87, 7.37 respectively). African Americans were 2.39 times as likely to have a 
scheduled nephrology visit as Whites (OR=2.39; 95%CI: 1.94, 2.94), and men were more likely 
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to have a scheduled nephrology visit than women pre-initiative (OR: 1.56; 95%CI: 1.34, 1.81).  
Individuals with hypertension were less likely to have a scheduled appointment pre-reporting 
initiative than those with no hypertension (OR= 0.73; 95% CI (0.54, 0.99). Similar results were 
observed for diabetes and CVD (diabetes (OR=1.01; 95% CI (0.78, 1.31); CVD (OR=0.78; 
95%CI (0.63, 0.95). Similar factors were found to be independently associated with having a 
scheduled nephrology visit post-initiative; eGFR level, race, sex, CKD risk factors, and distance 
travelled to UNC. Those with an eGFR between 15-29 mL/min/1.73m
2 
were 4.73 times more 
likely to be scheduled than those with eGFR between 30-59 mL/min/1.73m
2
 (OR=4.73 95% CI: 
3.89, 5.75). African Americans were 71% more likely to be scheduled post-initiative than those 
patients of other races (OR=1.71; 95% CI: 1.45, 2.02) as shown in Table 9. 
 
Changes in eGFR Levels  
Changes in eGFR levels were evaluated for those patients with subsequent SCr 
measurements 12 months after the initial nephrology visit (n=872) or 12 months after the initial 
low lab (n=3165, for those without a nephrology visit).  Overall, nearly 50% had an 
improvement in kidney function, 6% had a deterioration of kidney function and 44% had no 
change in stage 12 months after their initial appointment or low lab (Data not shown).  
 
When examining changes in eGFR levels among those who had a nephrology 
appointment, there was a significant change in the proportion of those who had an improvement 
in kidney function pre and post reporting initiative (p=0.011). Thirty-eight percent observed a 
decrease in stage after automatic eGFR reporting as compared to 30 % before automatic eGFR 
reporting. Fewer people experienced a worsening of disease (increase in CKD stage) after 
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implementation of eGFR reporting compared to before reporting (12.9% vs. 14.4% respectively 
– Table 10).  There was a marginally significant increase in the proportion of people who had no 
change in the eGFR levels before eGFR reporting compared to after (p-value 0.05; 0.55 vs. 0.49, 
respectively – Table 10).  
 
Similar trends were observed among those who did not have a scheduled nephrology 
appointment. Twelve months after the initial low SCr lab there were 3,165 individuals with 
subsequent SCr measurements. Forty-two percent of these patients had no change in their eGFR 
levels, 54% regained some level of function (increase in eGFR level) and 3.4% lost further 
function in their kidneys (decrease in eGFR level - Data not shown). The trends in changes in 
eGFR levels before and after eGFR reporting among those with no nephrology appointment were 
similar to those who had a nephrology appointment. However,  there was a significantly higher 
proportion of people who had an increase in eGFR levels after automatic eGFR reporting than 
compared to before  automatic eGFR reporting (p<0.001; 62% vs. 44%), a fewer proportion of 
people had a decrease in eGFR levels (2% vs. 5%) and no change in eGFR (35.9% vs. 50.9%). 
For each level of eGFR, there was a significant difference in the changes in eGFR levels pre and 
post automatic eGFR reporting, with the large majority of the individuals having an increase in 
eGFR levels post automatic eGFR reporting compared to pre reporting for each baseline level of 
eGFR. 
 
The magnitude of the change in mean GFR levels was comparable before and after 
reporting. The values were also similar among those with and without a scheduled nephrology 
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appointment. One notable observation was that the range of mean changes was wider among 
those with no nephrology appointment compared to those with a scheduled. (Table 11) 
 
Discussion 
 We evaluated the impact of the automatic eGFR reporting initiative in a tertiary healthcare 
center. No differences were observed in the proportion of new nephrology referrals for patients 
screened pre-initiative compared to post-initiative.  Interestingly, the odds of obtaining a 
scheduled nephrology appointment were lower for individuals with known CKD risk factors, 
regardless of the eGFR reporting period than those without known risk factors.  After 
implementation of eGFR reporting, the majority of individuals with a scheduled nephrology 
appointment showed no change in CKD stage for up to 12 months, or had an improvement in 
kidney function (decrease in CKD stage).  This pattern was more pronounced in the post 
implementation phase of eGFR reporting. Post-implementation of eGFR reporting, the majority 
of those without a nephrology visit showed an improvement of kidney function in eGFR ensuing 
12 months, not influenced by baseline level of eGFR. The evaluation of change in eGFR levels 
indicated minimal to no impact on kidney outcomes as a result of eGFR reporting. 
 
 Studies have reported conflicting results regarding the impact automatic eGFR reporting has 
on consults and referrals [37, 68, 73, 74]. A Canadian study of adult patients from a tertiary 
health care center found that there was an increase in the absolute number of referrals after eGFR 
reporting; however there was no increase in the proportion of referrals.[73]  A US-based study of 
adults showed an increase in referrals for earlier stages of CKD but the increase was not 
sustained two years following the initiation of reporting[68]. Similarly a study from Ottawa 
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examined the ten-year impact of eGFR reporting using time series analysis and found a sudden 
but not sustained increase in nephrology consults [37]. Additionally a study evaluating the 
impact of eGFR reporting on the management of hospitalized patients in New York reported no 
increase in the number of nephrology consults[74]. We found an increase in nephrology referrals 
among those with eGFR levels <15mL/min/1.73m
2
, those 40-59 years of age and those with no 
health insurance. However, we did not examine the sustained impacts of automatic eGFR 
reporting.  
 
 Our study suggests that patients who are at greater risk for CKD (those with diabetes, 
hypertension and/or CVD) have lower odds of a scheduled nephrology appointment regardless of 
reporting period.   Additional analyses showed that there were low proportions of scheduled 
nephrology visits among patients with hypertension, diabetes and CVD after a low eGFR lab 
value was reported. While more than 90% of the patients with comorbidities had moderate eGFR 
levels 30-59 mL/min/1.73m
2
, it is possible that physicians may decide to focus on intervening 
and controlling the comorbidities while monitoring the kidney function before a making a 
nephrology referral.  
 
 One argument used to support the implementation of automatic eGFR reporting included 
improving early detection of CKD in hopes of reducing the downstream burden of complications 
from late nephrology referrals.  This argument has been tempered with the concern that 
automatic eGFR may lead to an increased number of unnecessary nephrology referrals, thereby 
overwhelming subspecialists and preventing access to nephrologists for individuals that truly 
require intervention [68, 71, 75, 76]. Moreover, one retrospective study showed that automatic 
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eGFR reporting increased nephrologists’ workload but did not reduce the frequency of referral 
for those with severe kidney disease (stage 4 or 5). [71] The findings from our study do not 
support these concerns. There was no significant increase in scheduled nephrology appointments 
pre- or post-automatic eGFR reporting periods, although improvements in kidney function were 
observed in post- automatic eGFR reporting period.  In fact, only 8% more individuals were 
found to have a significant improvement in their kidney function one year later post eGFR 
reporting compared to pre-eGFR reporting, among those scheduled for a nephrology visit.  We 
were not able to elucidate whether these individuals improved because they were cases of acute 
kidney injury that would resolve without subspecialty intervention, or if these individuals 
improved directly because of the management that was elicited through nephrology care.    
 
 A sensitivity analysis was conducted to estimate eGFR change at one year change in GFR 
levels among those who had two low SCr levels. The trend of a higher proportion of individuals 
improving or experiencing no change in GFR was the same among those with and without 
nephrology appointments and by reporting period. Therefore, the patterns observed may not 
solely be due to acute kidney injury, but may be indicative of the fact that eGFR reporting had no 
discernible impact on kidney outcomes in this study. 
 
 To our knowledge, this is the first published study to address the characteristics and the 
long-term impact of individuals that have been referred for nephrology care after the 
implementation of automatic eGFR reporting in a healthcare system. The representative nature of 
the population is strength of our study. The UNCHS provides care for a racially and 
economically diverse population of patients, and this study is representative of both the general 
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population of NC and the general demographics of the patients cared for in the healthcare 
system. Strength is the utilization of a large sample of individuals within an US based tertiary 
care hospital system with a combination of laboratory and patient level data. While it is 
encouraging to see that minorities have a greater rate of nephrology visits as expected, women 
have a noticeably low number of referrals, a finding that deserves further exploration in other 
settings.  
 
 Our study limitations include the lack of individual chart reviews and the inability to 
identify whether therapeutic plans were prescribed to patients as a result of their nephrology 
visit. Further, the limited availability of records resulted in a shorter pre-eGFR reporting time 
period that was not optimal, may have been insufficient as a baseline to examine the changes that 
occurred in association with the introduction of automated reporting of eGFR in a complex, 
tertiary healthcare center.  The use of ICD-9 codes may have resulted in misclassification of the 
comorbidities if they were not coded correctly; however, we do not expect any misclassification 
to be differential in this high-risk population.  Lastly, it is not possible to capture follow-up 
nephrology visits by health care providers outside of the UNCHS.  To the degree that this 
occurred it would have attenuated our estimates of the referrals for subspecialty nephrologists 
both prior to and after the introduction of the automated reporting of eGFR. 
 
 Overall, our study revealed no increased volume of referrals for subspecialty nephrologists 
following the implementation of automatic eGFR reporting in a tertiary health care center in the 
Southeast US.   We submit that future studies should strive to provide longer follow-up of these 
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individuals to assess whether an impact on the proportion of individuals progressing to ESKD 
care is observed in the longer term. 
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Table 7-Characteristics of UNC Healthcare System Patients* with One Low estimated 
Glomerular Filtration (eGFR) Lab Value (Overall and by Scheduled Nephrology Appointment 
status) 
 
Characteristics 
Overall 
N=(14,840) 
No 
Nephrology 
Appointment 
(N=12,684) 
Nephrology 
Appointment 
(N=2,156) 
 N (%) N (%) N (%) 
eGFR level
†
  30-59 mL/min/1.73m
2
 12,831  (86.5) 11,574(90.2) 1,257(9.8) 
15-29 mL/min/1.73m
2
 996  (6.7) 674(67.7) 322(32.3) 
 <15 mL/min/1.73m
2
 1,013  (6.8) 436(43.0) 577(57.0) 
Women 8,436  (56.8) 7,427(88.0) 1,009(12.0) 
      Men 6,404  (43.2) 5,257(82.1) 1,147(17.9) 
African-Americans
‡
 4,387  (29.6) 3,505(79.9) 882(20.1) 
Other race 1,215  (8.2) 1,037(85.3) 178(14.7) 
Whites 9,238  (62.3) 8,142(88.1) 1,096(11.9) 
Age: 18-24 years of age 241  (1.6) 149(61.8) 92(38.2) 
25-39 years of age 1,527  (10.3) 1,122(73.5) 405(26.5) 
40-59 years of age 7,392  (49.8) 6,235(84.3) 1,157(15.7) 
60-70 years of age 5,680  (38.3) 5,178(91.2) 502(8.8) 
Hypertension
§
 4,936  (33.3) 4,421(89.6) 515(10.4) 
Diabetes
§
 2,164  (14.6) 1,884(87.1) 280(12.9) 
Cardiovascular disease
§
 2,159  (14.5) 1,973(91.4) 186(8.6) 
No Health Insurance** 1,554  (12.8) 1,360(87.5) 194(12.5) 
Public Insurance 5,509  (45.5) 4,749(86.2) 760(13.8) 
Private Insurance 3,748  (30.9) 3,160(84.3) 588(15.7) 
Public & Private Insurance 1,301  (10.7) 1,062(81.6) 239(18.4) 
Missing Health Insurance information 2,728   2,353 375 
Miles traveled to UNC: Less than 20 miles
*** 
5,849  (43.8) 5,363(91.7) 486(8.3) 
20-49 miles  4,072  (30.5) 3,486(85.6) 586(14.4) 
50-99 miles  2,358  (17.6) 1,873(79.4) 485(20.6) 
More than 100 miles  1,089  (8.1) 831(76.3) 258(23.7) 
Missing Distance  1,472   1,131 341 
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Characteristics 
Overall 
N=(14,840) 
No 
Nephrology 
Appointment 
(N=12,684) 
Nephrology 
Appointment 
(N=2,156) 
 N (%) N (%) N (%) 
No Health Insurance** 1,554  (12.8) 1,360(87.5) 194(12.5) 
Public Insurance 5,509  (45.5) 4,749(86.2) 760(13.8) 
Private Insurance 3,748  (30.9) 3,160(84.3) 588(15.7) 
Public & Private Insurance 1,301  (10.7) 1,062(81.6) 239(18.4) 
Missing Health Insurance information 2,728   2,353 375 
Miles traveled to UNC: Less than 20 miles
*** 
5,849  (43.8) 5,363(91.7) 486(8.3) 
20-49 miles  4,072  (30.5) 3,486(85.6) 586(14.4) 
50-99 miles  2,358  (17.6) 1,873(79.4) 485(20.6) 
More than 100 miles  1,089  (8.1) 831(76.3) 258(23.7) 
Missing Distance  1,472   1,131 341 
*All data were derived from UNC Healthcare System data for 2004-2010. The study population included patients with at least one SCr lab value <60 
mL/min/1.73m2. Patients with unknown race, gender and age, and previous kidney disease were excluded. The Scheduled Nephrology Appointment status 
was determined whether or not an appointment was scheduled for the patient within one year following a low estimated Glomerular Filtration (eGFR) in the 
UNCHS. 
† eGFR level was determined based on the abbreviated Modification of Diet in Renal Disease (MDRD) equation.  
‡ Based on the race/ethnicity reported in medical record.  'Other' race includes all patients with race/ethnicity identified as American Indian, Asian/Pacific 
Islander, Hawaiian, or Other race. 
§ Patients with comorbidities identified in medical records (via ICD-9 codes) at least once within one year prior to clinic visit were identified classified as 
having Hypertension (401,402); Diabetes (250, 250.5, and 250.5); CVD (410-414,428, 429.2, 430-438) 
**Health insurance coverage was determined based upon the insurance that was identified in the medical records within 60 days of the visit. Private (Blue 
Cross, CHAMPUS, Commercial, HMO/PPO) Public (Medicaid, Medicare A, Medicare B), No Health Coverage (Self-Pay, Workers’ Compensation) Data 
are missing for patients with unknown insurance. 
***Miles traveled to UNCHS based upon the distance between UNCHS and patient address 
  
 58 
 
Table 8-Characteristics of UNC Healthcare System Patients* with One Low estimated 
Glomerular Filtration (eGFR) Lab Value by Scheduled Nephrology Appointment status and 
eGFR Reporting Period 
 
 
Pre-Initiative 
Jan 2004- April 2005 
 (N=5467) 
Post-Initiative 
May 2005- Dec 2009 
 (N=9,373) 
Characteristic 
No 
Nephrology 
Appointment 
Scheduled 
Appointment 
No 
Nephrology 
Appointment 
Scheduled 
Appointment 
 N (%) N (%) N (%) N (%) 
Overall 4,651 (85.1) 816 (14.9) 8,033 (85.7) 1.340 (14.3) 
eGFR level
†
  30-59 mL/min/1.73m
2
 4,059 (87.3) 476 (58.3) 7,515 (93.6) 781 (58.3) 
15-29 mL/min/1.73m
2
 316 (6.8) 146 (17.9) 358 (4.5) 176 (13.1) 
 <15 mL/min/1.73m
2
 276 (5.9) 194 (23.8) 160 (2.0) 383 (28.6) 
Women 2,719 (58.5) 387 (47.4) 4,708 (58.6) 622 (46.4) 
      Men 1,932 (41.5) 429 (52.6) 3,325 (41.4) 718 (53.6) 
African-Americans
‡
 1,389 (29.9) 342 (41.9) 2,116 (26.3) 540 (40.3) 
Other race 319 (6.9) 58 (7.1) 718 (8.9) 120 (9.0) 
Whites 2,943 (63.3) 416 (51.0) 5,199 (64.7) 680 (50.7) 
Age: 18-24 years of age 59 (1.3) 35 (4.3) 90 (1.1) 57 (4.3) 
25-39 years of age 390 (8.4) 173 (21.2) 732 (9.1) 232 (17.3) 
40-59 years of age 2,195 (47.2) 408 (50.0) 4,040 (50.3) 749 (55.9) 
60-70 years of age 2,007 (43.2) 200 (24.5) 3,171 (39.5) 302 (22.5) 
Hypertension
§
 853 (18.3) 121 (14.8) 3,568 (44.4) 394 (29.4) 
Diabetes
§
 413 (8.9) 73 (8.9) 1,471 (18.3) 207 (15.4) 
Cardiovascular disease
§
 383 (8.2) 50 (6.1) 1,590 (19.8) 136 (10.1) 
No Health Insurance** 296 (11.6) 48 (9.3) 1,064 (13.7) 146 (11.5) 
Public Insurance 1,146 (45.1) 224 (43.6) 3,603 (46.3) 536 (42.3) 
Private Insurance 803 (31.6) 166 (32.3) 2,357 (30.3) 422 (33.3) 
Public & Private Insurance 297 (11.7) 76 (14.8) 765 (9.8) 163 (12.9) 
Missing Health Insurance information 2,109  302  244  73  
Miles traveled to UNC: Less than 20 
miles
*** 
1,732 (44.0) 174 (26.2) 3,631 (47.7) 312 (27.1) 
20-49 miles  1,192 (30.3) 205 (30.8) 2,294 (30.1) 381 (33.1) 
50-99 miles  721 (18.3) 189 (28.4) 1,152 (15.1) 296 (25.7) 
More than 100 miles  295 (7.5) 97 (14.6) 536 (7.0) 161 (14.0) 
Missing Distance  711  151  420  190  
*All data were derived from UNC Healthcare System data for 2004-2010. The study population included patients with at least one SCr lab value <60 mL/min/1.73m2. Patients with 
unknown race, gender and age, and previous kidney disease were excluded. The Scheduled Nephrology Appointment status was determined whether or not an appointment was 
scheduled for the patient within one year following a low estimated Glomerular Filtration (eGFR) in the UNCHS. . The eGFR reporting period was determined by the timing of the 
patient visit relative to the implementation of the automatic eGFR reporting initiative in the UNCHS before April 2005 (Pre-); after April 2005 (Post-). 
† eGFR level was determined based on the abbreviated Modification of Diet in Renal Disease (MDRD) equation.  
‡ Based on the race/ethnicity reported in medical record.  'Other' race includes all patients with race/ethnicity identified as American Indian, Asian/Pacific Islander, Hawaiian, or Other 
race. 
§ Patients with comorbidities identified in medical records (via ICD-9 codes) at least once within one year prior to clinic visit were identified classified as having Hypertension 
(401,402); Diabetes (250, 250.5, and 250.5); CVD (410-414,428, 429.2, 430-438) 
**Health insurance coverage was determined based upon the insurance that was identified in the medical records within 60 days of the visit. Private (Blue Cross, CHAMPUS, 
Commercial, HMO/PPO) Public (Medicaid, Medicare A, Medicare B), No Health Coverage (Self-Pay, Workers’ Compensation) Data are missing for patients with unknown insurance.  
***Miles traveled to UNCHS based upon the distance between UNCHS and patient address  
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Table 9- Factors Associated with a Scheduled Nephrology Visit by eGFR reporting Period 
 
  Overall 
Pre-Initiative 
Jan2004-April 2005  
Odds of having a 
scheduled nephrology 
appointment Ratio 
 (95% CI)   
 Post-Initiative 
May 2005-Dec 2009 
Odds of having a 
scheduled nephrology 
appointment Ratio 
 (95% CI) 
eGFR level
b
   
30-59 mL/min/1.73m
2
 12,831  (86.5) Ref. Ref. 
15-29 mL/min/1.73m
2
 996  (6.7) 3.94(3.17,4.90) 4.73(3.89,5.75) 
 <15 mL/min/1.73m
2
 1,013  (6.8) 5.99(4.87,7.37) 23.03(18.88,28.09) 
Age: 18-24 241  (1.6) 3.19(2.07,4.91) 3.42(2.43,4.80) 
25-39 1,527  (10.3) 2.39(1.94,2.94) 1.71(1.45,2.02) 
40-59 7,392  (49.8) Ref. Ref. 
60-70 5,680  (38.3) 0.54(0.45,0.64) 0.51(0.45,0.59) 
White race 241  (1.6) 3.19(2.07,4.91) 3.42(2.43,4.80) 
African American race 1,527  (10.3) 2.39(1.94,2.94) 1.71(1.45,2.02) 
Other race 7,392  (49.8) Ref. Ref. 
Women 8,436  (56.8) Ref. Ref. 
     Men 6,404  (43.2) 1.56(1.34,1.81) 1.63(1.46,1.84) 
No History of CVD 12,681  (85.5) Ref. Ref. 
History of CVD 2,159  (14.5) 0.73(0.54,0.99) 0.46(0.38,0.55) 
No History of Diabetes 12,676  (85.4) Ref. 12,676  (85.4) 
History of Diabetes 2,164  (14.6) 1.01(0.78,1.31) 0.82(0.70,0.96) 
No History of Hypertension 9904 (66.7) Ref. Ref. 
History of Hypertension 4,936  (33.3) 0.78(0.63,0.95) 0.52(0.46,0.59) 
Miles traveled to UNC: Less 
than 20 miles 5,849  (43.8) Ref. Ref. 
Traveled 20 to 49 miles  4,072  (30.5) 1.71(1.38,2.12) 1.93(1.65,2.26) 
Traveled  50 to 99 miles 2,358  (17.6) 2.61(2.09,3.26) 2.99(2.52,3.55) 
Traveled more than 100 miles 1,089  (8.1) 3.27(2.48,4.32) 3.50(2.83,4.32) 
No insurance 1,554  (12.8) Ref. Ref. 
Private insurance only 5,509  (45.5) 1.21(0.86,1.69) 1.08(0.89,1.32) 
Public Insurance only 3,748  (30.9) 1.27(0.90,1.80) 1.30(1.07,1.60) 
Public and Private insurance 1,301  (10.7) 1.58(1.06,2.34) 1.55(1.22,1.98) 
a Odds of Scheduled Nephrology Appointment Ratios: Odds of having a Scheduled Nephrology Appointment (group1) vs.  Odds of No 
scheduled Appointment (Reference) 
1 
  
 
Table 10- One year Within Patient Changes in eGFR Levels by Scheduled Nephrology Appointment Status 
 
 Had a Scheduled Nephrology Appointment  
 (N=872) 
No Nephrology Appointment 
(N=3165) 
 Before eGFR 
reporting 
(N=416) 
After eGFR 
reporting 
(N=456) 
 p-value 
Before eGFR 
reporting 
(N=1369) 
After eGFR 
reporting 
(N=1796) 
p-value 
Overall       
Decrease in CKD Stage
1 
125(30.0) 174(38.2) 0.011 602(44.0) 1,113(62.0) <0.001 
No Change
2 
231(55.5) 223(48.9) 0.050 697(50.9) 645(35.9) <0.001 
Increase in CKD Stage
3 
60(14.4) 59(12.9) 0.524 70(5.1) 38(2.1) <0.001 
  
 
1
Decrease in CKD Stage is change in GFR level equivalent to a CKD stage lower than initial GFR level 
 2
No Change in CKD Stage is where initial GFR levels are equivalent to subsequent GFR levels. 
 3
Increase in CKD Stage is change in GFR level equivalent to a CKD stage higher than the initial GFR level 
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Table 11-Mean GFR Level One-year Within Patient Change by Scheduled Nephrology Appointment Status and Change in CKD Stage
1 
 
 Had a Scheduled Nephrology Appointment 
(N=872) 
No Nephrology Appointment 
(N=3165) 
 Before eGFR 
reporting (N=416) 
After eGFR reporting 
(N=456) 
Before eGFR reporting 
(N=1369) 
After eGFR reporting 
(N=1796) 
         
 Mean 
GFR 
Change 
(Std Dev) 
Range 
Mean GFR 
Change 
(Std Dev) 
Range 
Mean GFR 
Change 
(Std Dev) 
Range 
Mean GFR 
Change 
(Std Dev) 
Range 
Decrease in 
CKD Stage
1 
29.21 
(21.86) 116.59 
32.22 
(24.44) 132.49 
24.57 
(19.75) 142.36 
28.88 
(25.84) 222.94 
Increase in 
CKD Stage
2 
-17.42 
(11.32) 48.03 
-20.32 
(11.56) 47.05 
-18.84 
(10.56) 51.92 
-19.46 
(12.19) 55.10 
No Change
3 
-1.05 
(6.92) 41.24 
-1.62 
(8.01) 46.75 
-0.87 
(7.82) 55.17 
-0.65 
(8.80) 56.85 
 
 
1
Decrease in CKD Stage is change in GFR level equivalent to a CKD stage lower than initial GFR level 
 2
Increase in CKD Stage is change in GFR level equivalent to a CKD stage higher than the initial GFR level 
 3
No Change in CKD Stage is where initial GFR levels are equivalent to subsequent GFR levels. 
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CHAPTER SIX: DISCUSSION 
 
Study Rationale 
Several studies reported an increasing temporal trend in frequency of occurrence of CKD, [1-
4] with the prevalence of CKD ranging from 3% to 30 %. [5-11]. CKD and ESKD lower patient 
quality of life, cause premature morbidity and mortality, and lead to economic burden on 
individuals, health care systems and society.[12] Early diagnosis and management of kidney 
disease on the other hand can delay the progression to ESKD and avert the cardiovascular 
sequelae associated with CKD [13, 14]. Despite the high population burden of CKD, awareness 
and detection of kidney disease in the US is low among consumers and providers of healthcare 
services. [3, 15-19].  Furthermore, despite knowledge that early detection and medical 
management are key to slowing the progression of kidney disease, delayed referrals to 
nephrologists are common.   
 
Automatic eGFR reporting initiatives were implemented by international and US-based 
healthcare organizations and clinical laboratories to increase reporting efficiency, facilitate the 
early diagnosis of Chronic Kidney Disease (CKD), and improve early medical management to 
minimize CKD burden. International population studies have shown that automatic eGFR 
reporting resulted in increased CKD detection, referrals, consults, and first time visits to 
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nephrology clinics [20-24]. In contrast, the impact of eGFR reporting in US healthcare systems 
remains unclear [25-27]. 
Specific Aims 
This study sought to assess whether automatic eGFR reporting has a measurable effect on 
CKD detection and patient care, and to identify patient characteristics related to benefit from 
eGFR reporting in terms of detection and referral. To achieve this goal we addressed the 
following aims:   
Specific Aim 1: To quantify the detection of  CKD detection prior to and following the 
implementation of automatic eGFR reporting among adults patients who had at least one 
SCr measurement with an eGFR measurement below 60ml/min/1.73m
2 
seen in the UNC 
Healthcare System (UNCHS) between January 2004 and December 2010.  
 
Specific Aim 2: To quantify the proportion of adults who had a second SCr measurement 
after an initial eGFR <60 ml/min/1.73m
2
 before and after the implementation of 
automatic eGFR reporting seen in the UNC Healthcare System (UNCHS) between 
January 2004 and December 2009. 
 
Specific Aim 3: To quantify the detection of clinically identified CKD before and after 
the implementation of automatic eGFR reporting among adult patients with lab-verified 
moderate to severe CKD (i.e. two eGFR measurements below 60ml/min/1.73m
2
) seen in 
the UNC Healthcare System (UNCHS) between January 2004 and August 2009.  
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Specific Aim 4 : To examine the proportion of nephrology referrals to UNC Nephrology 
clinics for adult patients with stage 3 CKD or higher before and after the implementation 
of automatic eGFR reporting in the UNCHS 
Summary of Findings  
To examine the impact of the eGFR reporting initiative on CKD detection in a tertiary 
care health care institution we estimated 1-year cumulative incidence (CI) and difference (CID) 
of CKD detection in the study cohort pre- and post-initiative.  Patient characteristics associated 
with CKD detection were then assessed, overall and by reporting period. 
 
Following the introduction of automatic eGFR reporting, CKD detection increased by 
9%, with a greater increase in detection found among those with moderate CKD (Stage III, 
eGFR: 30-59 mL/min/1.73m
2
). The increase in CKD detection post eGFR reporting initiative, 
was greatest in older adults, males, whites and those with a history of hypertension, diabetes and 
CVD. Although a moderate increase in CKD detection was observed overall, the greatest 
increase was in the second year of implementation, and the increase was not sustained in 
subsequent years. 
 
Prior to the reporting initiative the following factors were statistically independently 
associated with CKD detection: eGFR level, age, race and gender. Factors that we found to be 
independently associated with CKD detection post-initiative were eGFR level, race, and 
comorbidities. Those with lower eGFR levels (15-29 mL/min/1.73m
2
) were almost 2 times as 
likely to be detected as those with eGFR levels between 30-59 mL/min/1.73m
2
. Following 
implementation of the eGFR reporting initiative, CKD was more likely to be detected among 
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African Americans than in whites and among those with a history of CVD, hypertension and 
diabetes than those without the comorbidity.  
  
We found that the overall CKD detection rates were low in this patient population, 
despite the broad education efforts that made to increase CKD awareness within the institution 
and North Carolina. Although surprising for this institution, similar results have been reported by 
others.[6, 27, 40] 
 
We also sought to examine whether the introduction of the automatic eGFR reporting 
initiative was associated with the number of scheduled nephrology appointments, to identify the 
patient characteristics associated with scheduling nephrology appointments, and to evaluate a 
potential impact of automated eGFR reporting on the temporal trends in patient’s kidney 
function among those with and without a scheduled nephrology appointment. No increase in the 
number of referrals for subspecialty nephrologists following the implementation of automatic 
eGFR reporting was observed, which represents an important finding since it does not support 
the generally held expectation that eGFR reporting increases the workload for nephrologists.  
 
Additionally, we observed that the odds of obtaining a scheduled nephrology 
appointment were lower for individuals with known CKD risk factors (hypertension, CVD, and 
diabetes), regardless of the eGFR reporting period.  We further observed that following 
implementation of eGFR reporting, the majority of patients with a scheduled nephrology 
appointment showed no change in CKD stage at one year after the appointment, or experienced 
an improvement in kidney function (decrease in CKD stage). This pattern was more pronounced 
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in the post-initiative phase of eGFR reporting. Post-implementation of the eGFR reporting 
initiative, the majority of those without a nephrology visit showed an improvement of kidney 
function in eGFR during the ensuing 12 months, not influenced by baseline level of eGFR. The 
evaluation of change in eGFR levels indicated minimal to no impact on kidney outcomes as a 
result of eGFR reporting, findings which were contrary to a priori expectations. Although we are 
unable to infer a cause for these findings we propose that the improvement could be indicative of 
acute kidney injury cases that would have resolved without subspecialty intervention.  
  
 In summary, this dissertation sought to evaluate the impact of automatic eGFR reporting 
within UNCHS. We found a slight non-significant increase in CKD detection as a result eGFR 
reporting but  no increase in nephrology referrals or significant changes in kidney function at one 
year of follow-up. We conclude that automatic eGFR reporting had no discernible association 
with  CKD detection or patterns of patient care with the UNC Health System.  
 
Strengths and Limitations  
This study utilized a large sample of individuals within an US based tertiary care hospital 
system with a combination of laboratory and patient level data to explore the study objectives. 
Several logistical, operational and methodological challenges were encountered in conducting 
this research. Data availability emerged as a significant challenge in this study. UNCHS data was 
only available from 2004-2010, which only included 15 months prior to the implementation of 
the eGFR reporting initiative for this study. The short timeframe for pre-eGFR reporting 
initiative may have been insufficient to examine the true association of detection and could lead 
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to misclassification of comorbidities and patient characteristics. To address this limitation, the 
timeframe for identification of comorbidities and patient characteristics was limited to one year 
prior to the clinic visit date associated with the second low eGFR measurement, pre- and post- 
initiative, to minimize differential misclassification with respect to eGFR reporting period.  
 
An operational as well as methodological challenge for this study derived UNCHS’ status 
of referral center.  As a result it is possible that patients had a second low eGFR measurement at 
an ambulatory center outside of UNHCS and therefore have a diagnosis of CKD prior to 
documentation at UNCHS of a second low eGFR. A sensitivity analysis was conducted to 
examine the risk of CKD detection among patients after their first low eGFR value. Results from 
the sensitivity analyses indicated similar detection patterns as those in the overall study, with a 
lower CKD detection post-initiative reporting, than pre- initiative reporting. The detection rates 
among this group did not differ with respect to magnitude or direction. Thus, selection bias due 
to the definition of lab-verified CKD should not significantly alter these results. The referral 
center status of UNCHS could also make it difficult to capture follow-up nephrology visits by 
health care providers outside of the UNCHS.   To the degree that this occurred it would have 
attenuated our estimates of the referrals for subspecialty nephrologists both prior to and after the 
introduction of the automated reporting of eGFR. 
 
A further concern is potential misclassification. Current CKD guidelines define CKD as 
persistent kidney dysfunction with or without the presence of kidney damage. This study could 
only assess kidney dysfunction through serum creatinine measures and not the presence of 
protein in a patient’s urine. Patients with kidney damage who would be identified clinically as 
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having CKD were not identified in our study. The use of ICD-9 codes alone may have resulted in 
misclassification of the comorbidities if they were not coded correctly; however, we do not 
expect any misclassification to be differential in this high-risk population.   
 
This study used electronic health records (EHR) as the main data source. EHR proved to 
be a rich source of data for this study and for many other research studies. However the use of 
EHR was also translated into an operational limitation. EHR data are generally not captured for 
research purposes and many key definitions and decisions must be made to utilize the data to 
answer research questions. With the advent of the Health Insurance Portability and 
Accountability Act that requires all health organizations (large and small) to implement the use 
electronic health records, there has been an increase in the use of EHR for research purposes 
because it minimizes the need to collect study data by using data that was already collected.  
However, caution should be exercised when studies use EHR for research purposes since careful 
attention to study definitions and study designs is required to ensure data quality. Much time and 
attention to detail was required to arrive at an appropriate study design and definitions for this 
study, and to ensure that the data were valid and with minimal opportunities for bias.  
 
This study also had several strengths, one of which the examination of the characteristics 
and long-term impact of individuals that have been referred for nephrology care after the 
implementation of automatic eGFR reporting in a healthcare system; to our knowledge, this is 
the first study. The nature of the patient population is another strength of this study in that 
UNCHS provides care for a racially and economically diverse population of patients drawn from 
a wide geographic area that includes urban and rural sectors.  These features favor the 
 69 
 
generalizability of these findings as regards the patient population, although our results are seen 
as most applicable to tertiary health care settings.  . 
 
Public Health Impact 
Although our results indicate that introduction of automated eGFR reporting in the 
UNCHS was not associated with a significant temporal increase in CKD detection and pattern of 
specialty care by nephrology, the study offers some insights on the factors that may deserve 
attention in order to achieve the desired impact of eGFR reporting. Based on our results and the 
overall low CKD detection rates observed we conclude that a more visible and sustained 
educational effort is likely required to increase awareness among patients and health care 
professionals of a system-wide eGFR reporting, its information value, and its actionable features. 
Such a campaign would likely benefit from information about CKD and the importance of CKD 
detection. Further, given that we observed no increase in the workload of nephrologists but did 
identify a temporal trend of kidney function improvement following the introduction of eGFR 
reporting, replication of these results in other health care settings and institutions that implement 
eGFR reporting is recommended to achieve clarity on the anticipated – but undocumented – 
greater engagement of nephrology specialist care resources as a result of automatic eGFR 
reporting.   Lastly, based on our experience in this study we submit that electronic health records 
can be an asset as a resource for clinical research, although at cost of great attention to data 
completeness and data quality concerns, and reliance on detailed data management and research 
protocols. 
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As CKD continues to be a public health issue worldwide and the costs associated to treat 
those who are in the final stages of CKD continue to rise, it is of particular interest to explore 
avenues for early detection that enables early medical management and therapeutic interventions.  
Similarly, the identification of patient characteristics associated with detection and referral 
practices (e.g. SES, health care access, gender, insurance status, etc.) is of interest if it allows 
investigators to conduct targeted approaches to identify those individuals who may not be 
regularly screened or have a delay in referrals resulting in more severe and irreversible disease. 
A systematic approach such as automatic eGFR reporting broadens the scope of the detection 
efforts well beyond targeted screenings, although thus far it is mostly applied to selected patient 
populations.  Far from being representative of the general population, the majority of patients 
seen in a tertiary care referral system represent a population enriched with morbidities and thus 
also their antecedent risk factors. The rationale for automatic reporting of eGFR in high risk 
populations such as most of the patients seen in the UNCHS is for earlier identification of those 
with kidney disease among them, to achieve earlier interventions to reduce progression of the 
disease to the end stages, and its burden of morbidity, mortality and economic drain.  
Future Directions 
 We submit that further study to explore the effects attributed to automatic eGFR reporting 
policies on CKD detection and patient kidney function outcomes are warranted. Follow-up 
studies are encouraged given the need for sufficiently long pre- and post-initiative follow-up 
periods, as required to assess clinically meaningful and public health relevant effects that can be 
attributed to  eGFR. The operational definition of CKD for such studies should include the 
characterization of kidney damage through the presence of proteinuria, to  provide a more 
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complete picture of the putative benefits from an automatic eGFR reporting policy. Also based 
on the experience in this study we submit that more precise measures of nephrology referral 
deserve to be considered to advance our knowledge in this field.   
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APPENDIX 1: DESCRIPTION OF NCTRACS DATA SOURCE GUIDE
  
  
Files Received from NC TRACS 
Dataset name 
Dataset patient 
identifiers 
Description of 
dataset 
Data Structure and 
Development 
DX1.xls- DX17.xls 
patient_sk account_sk 
eff_date 
Contains all 
diagnosis identified 
for patients in 
UNCHS 
There is more than one DX 
for a given visit date. 
Restructured to include all 
identified diagnoses per 
patient per date on one 
observation. 
Postalcode1.xls-
Postalcode17.xls 
patient_sk account_sk 
update_ts 
Contains 
information on the 
billing addresses for 
patients. The 
update_ts variable 
indicates the date the 
address was updated 
in the system. 
There were more than one 
observation for a given 
patient at times. The address 
that indicates the location the 
patient lived at during the 
identified clinic visits. 
Demog1.xls-
Demog17.xls 
patient_sk 
medical_record_number 
Contains the race, 
dob, gender of 
patients in UNCHS 
Only one observation for 
each patient_sk 
Echart1.xls-
echart17.xls 
patient_sk account_sk 
echartdate 
Contains the height 
and weight of 
UNCHS patients 
Admis_wt, echart_et  and 
echartht are on separate 
observations for a given date 
Restructured to capture the 
height and weight for each 
patient on the same clinic 
visit date. 
Lab1.xls-Lab17.xls patient_sk lab1date 
Contains the lab 
information for the  
flagged GFR labs 
There was more than one 
observation for a given date, 
but that date corresponds to 
another lab pair indicated by 
pat_labid. 
7
3
 
7
1
 
  
  
Dataset name 
Dataset patient 
identifiers 
Description of 
dataset 
Data Structure and 
Development 
Outpatientvisits1.xls-
Outpatientvisits17.xls 
patient_sk account_sk 
patient_visit_date 
identifies the clinic 
the patient was seen 
in during the 
UNCHS visit 
There were multiple clinic 
listings on a visit date. 
Restructured to capture all 
clinic visits on the same date 
for each patient. 
Payor1.xls-
Payor17.xls 
patient_sk account_sk 
payor_date 
Identifies the billing 
payor for the 
UNCHS visit 
Only one observation for 
each patient_sk and 
payor_date 
Problems1.xls-
Problems17.xls 
patient_sk account_sk 
problem_onset_date 
identifies any 
comorbidities the 
patient had in 
medical record 
There was more than one 
observation for a given date. 
Restructured to include all 
identified problems per 
patient per date on an 
observation. 
Visits1.xls-
Visits17.xls 
patient_sk account_sk 
admission_date 
identifies the 
inpatient admission 
information for the 
corresponding 
UNCHS visit 
There is only one clinic 
information for each 
admission date. 
Vitals1.xls-
Vitals17.xls 
patient_sk account_sk 
vital_date 
Corresponds to 
height and weight 
for a UNCHS visit 
There is only one weight and 
height for each visit  (Never 
able to determine units so 
this was not used) 
SKMRNList 
 
patient_sk 
Crosswalk table 
between patient SKs 
and their actual 
medical record 
numbers 
There is only one record per 
person. 
7
2
 
7
4
 
  
  
 
 
Dataset name 
Dataset patient 
identifiers 
Description of 
dataset 
Data Structure and 
Development 
NephAppts 
 
Patient MRN 
 
Appointment 
scheduler data for 
Nephrology clinic 
appointments earlier 
than 12/31/2010 
 
There is only one record per 
person. 
NephVisits 
 
patient_sk 
Hospital billing data 
for Nephrology 
clinic visits earlier 
than 12/31/2010 
 
There is only one record per 
person. 
NephVisitInsurers 
 
patient_sk 
Patients' insurance 
data for Nephrology 
clinic visits earlier 
than 12/31/2010 
 
There is only one record per 
person. 
7
5
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APPENDIX 2: CLINICAL AND PROVIDER DATA SOURCE SUMMARY 
  
 
 
  
 Description How variable 
was 
categorized 
Data Source NCTRACS 
Source 
Notes 
Characteristics      
Demographics   
Patient 
Information 
     
Patient_sk NCTracs unique patient 
identifier 
 All datasets 
from 
NCTRACs 
  
Medical Record 
Number 
Unique identifier for patients 
seen in UNCHS 
 WEBCIS/ 
Accounting 
Demog.xls  
Residence 
Billing Zip 
code   
  WEBCIS/ 
Accounting 
Addresses.xls  
Inpatient 
indicator 
Identified is patient was seen in 
an inpatient clinic 
 Accounting Visits.xls  
Outpatient 
indicator 
Identified is patient was seen in 
an Outpatient clinic 
 Accounting Outpatients.xls  
Diagnosis 
codes 
Will be used to determined 
indication of CKD diagnosis and 
other co morbidities.  
 WEBCIS & 
UNC  P&A 
DX  
Nephrology 
visit type 
Will be used to determine if 
patient was seen in a nephrology 
clinic within one year of CKD 
diagnosis 
1=New, 
2=Consult, 
3=return 
UNC P &A Visits  
7
7
 
  
 
  
 Description How variable 
was 
categorized 
Data Source NCTRACS 
Source 
Notes 
Age via Date of 
birth 
Patient’s age at clinic 
visit 
Continuous 
18-39 
40-59 
60-69 
WEBCIS/ 
Accounting 
Demographics,   
Sex Patient’s sex 0=Male 
1= Female 
WEBCIS/ 
Accounting 
Demog  
Race  Patient’s race/ ethnicity 0=White 
1=African 
American 
2=Other  
 
WEBCIS/ 
Accounting 
Demog  
Health Insurance Patient’s type of 
insurance 
0= No Insurance 
1= Public 
2=Private 
3=Public and 
Private 
4=Missing Health 
Insurance 
information 
WEBCIS/ 
Accounting 
Payor  
Weight Patient’s weight (kg) Continuous WEBCIS/ E-
chart 
Vitals and echart This information 
was not used. 
NCTraCS could 
not clarify the unit 
types for the data. 
Height Patient’s height (m) Continuous WEBCIS/ E-
chart 
Vitals and echart This information 
was not used. 
NCTraCS could 
not clarify the unit 
types for the data. 
7
8
 
  
 
  
 Description How variable 
was categorized 
Data Source NCTRACS 
Source 
 
Patient’s 
Residence 
The billing zip code of 
the patient 
 WEBCIS/ 
Accounting 
Addresses This variable was  
used to determine 
distance from 
UNCHS 
Hypertension Has diagnosis of 
hypertension indicated 
with an ICD-9 code 
(401, 401.1, 401.1, 
401.9, 402, 403, or 404) 
  
0= Normotensive 
1= Hypertensive 
Accounting Problems and DX  
Diabetes 
 
Has diagnosis of 
diabetes indicated with 
an ICD-9 code (250, 
250.4, 250.5, 362.01, or 
362.02)  
0= Non-diabetic 
1= Diabetic 
Accounting Problems and DX  
CHD Has diagnosis of CHD 
indicated with an ICD-9 
(410 to 414, 429.2) 
  Problems and DX  
CVA 
 
Has diagnosis of CVA 
indicated with an ICD-9 
code (430 to 438) 
 Accounting Problems and DX  
Heart Failure Has diagnosis of HF 
indicated with an ICD-9 
code (428) 
  Problems and DX  
MI Has diagnosis of AMI  
indicated with an ICD-9 
code (410) 
 Accounting Problems and DX  
Obesity 
 
Calculated using the 
height and weight 
obtained from charts 
0= Normal 
1=Obese 
WEBCIS Calculated  No calculated 
because weight 
and height could 
not be verified 
7
9
 
  
 
 
 Description How variable 
was categorized 
Data Source NCTRACS 
Source 
 
    Laboratory 
Results 
     
Serum Creatinine Reported from metabolic 
chemistry 7 or 10 panels. 
 Labs/ WEBCIS Labs  
Estimated 
glomerular 
filtration rate  
(eGFR ) 
The estimated value 
using the MDRD 
equation. 
Continuous Labs/ WEBCIS Labs Calculated for the 
values before 
April 2005 and the 
reported value for 
those after April 
2005. 
Provider 
information 
     
Date of Service The date of the clinic 
visit. 
 WEBCIS Labs  
Scheduled 
Appointment 
Indicator that identifies 
whether or not a patient 
has a scheduled 
Nephrology appointment 
 Accounting Nephvisits and 
NephApts 
 
Change in Kidney 
Function 
This indicates the 
changes in the eGFR 
levels from initial to 
subsequent eGFR 
1= Decrease in 
function 
0= No Change  
2= Improvement 
in kidney 
function 
Labs Labs Calculated from 
the difference 
between initial 
eGFR reading and 
subsequent eGFR 
reading 
      
8
0
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